

Extracellular vesicles from oviductal and uterine fluids supplementation in sequential in vitro culture improves bovine embryo quality

Cláudia Lima Verde Leal

Universidade de São Paulo Faculdade de Zootecnia e Engenharia de Alimentos: Universidade de Sao Paulo Faculdade de Zootecnia e Engenharia de Alimentos

Karina Cañón-Beltrán

INIA: Instituto Nacional de Investigacion y Tecnologia Agraria y Alimentaria

Yulia N Cajas

INIA: Instituto Nacional de Investigacion y Tecnologia Agraria y Alimentaria

Meriem Hamdi

INIA: Instituto Nacional de Investigacion y Tecnologia Agraria y Alimentaria

Aracelli Yaryes

INIA: Instituto Nacional de Investigacion y Tecnologia Agraria y Alimentaria

María Gemma Millán de la Blanca

INIA: Instituto Nacional de Investigacion y Tecnologia Agraria y Alimentaria

Paula Beltrán-Breña

INIA: Instituto Nacional de Investigacion y Tecnologia Agraria y Alimentaria

Rosane Mazzarella

Universidade de São Paulo Faculdade de Zootecnia e Engenharia de Alimentos: Universidade de Sao Paulo Faculdade de Zootecnia e Engenharia de Alimentos

Juliano Coelho da Silveira

Universidade de São Paulo Faculdade de Zootecnia e Engenharia de Alimentos: Universidade de Sao Paulo Faculdade de Zootecnia e Engenharia de Alimentos

Alfonso Gutiérrez-Adán

INIA: Instituto Nacional de Investigacion y Tecnologia Agraria y Alimentaria

Encina González

Universidad Complutense de Madrid Facultad de Veterinaria

Dimitrios Rizos (✉ drizos@inia.csic.es)

INIA: Instituto Nacional de Investigacion y Tecnologia Agraria y Alimentaria <https://orcid.org/0000-0001-6813-3940>

Keywords: exosomes, miRNAs, embryo development, cryopreservation, lipid metabolism, oviduct, uterus, cattle.

Posted Date: April 21st, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1553800/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

1 **Extracellular vesicles from oviductal and uterine fluids supplementation in**
2 **sequential in vitro culture improves bovine embryo quality**

3 **Cláudia Lima Verde Leal^{1,2*}, Karina Cañón-Beltrán^{1,3}, Yulia N Cajas^{1,4}, Meriem**
4 **Hamdi¹, Aracelli Yaryes¹, María Gemma Millán de la Blanca¹, Paula Beltrán-**
5 **Breña¹, Rosane Mazzarella², Juliano Coelho da Silveira², Alfonso Gutiérrez-**
6 **Adán¹, Encina González^{1,5}, Dimitrios Rizos^{1*}**

7 ¹Department of Animal Reproduction, National Center Institute for Agriculture and
8 Food Research and Technology (CSIC-INIA), 28040, Madrid, Spain.

9 ²Department of Veterinary Medicine, Faculdade de Zootecnia e Engenharia de
10 Alimentos, Universidade de São Paulo (FZEA-USP), Pirassununga, Brazil

11 ³Facultad de Ciencias Agrarias y Ambientales, Programa de Medicina Veterinaria,
12 Fundación Universitaria Juan de Castellanos, Tunja, Colombia.

13 ⁴Laboratorio de Biotecnología de la Reproducción Animal, Facultad de Ciencias
14 Agropecuarias, Universidad de Cuenca (UC), EC010205, Cuenca, Ecuador.

15 ⁵Department of Anatomy and Embryology, Veterinary Faculty-Universidad
16 Complutense de Madrid (UCM), Madrid, Spain

17 *** Correspondence:**

18 Cláudia Lima Verde Leal

19 clvleal@usp.br

20 Dimitrios Rizos

21 drizos@inia.csic.es

22

23 **Abstract**

24 **Background:** In vitro production of bovine embryos is a well-established technology,
25 but the in vitro culture (IVC) system still warrants improvements, especially regarding
26 embryo quality. This study aimed to evaluate the effect of extracellular vesicles (EVs)
27 isolated from oviductal (OF) and uterine fluid (UF) in sequential IVC on the
28 development and quality of bovine embryos. Zygotes were cultured in SOF
29 supplemented with either BSA or EVs-depleted fetal calf serum (dFCS) in the presence
30 (BSA-EV and dFCS-EV) or absence of EVs from OF (D1 to D4) and UF (D5 to D8),
31 mimicking in vivo conditions. EVs from oviducts (early luteal phase) and uterine horns
32 (mid-luteal phase) from slaughtered heifers were isolated by Size Exclusion
33 Chromatography. Blastocyst rate was recorded on Days 7-8 and their quality was
34 assessed based on lipid contents, mitochondrial activity and total cell numbers, as well
35 as survival rate after vitrification. Relative mRNA abundance for lipid metabolism-
36 related transcripts and levels of active hormone-sensitive lipase (pHSL) proteins were
37 also determined. Additionally, the expression levels of 383 miRNA in OF- and UF-EVs
38 were assessed by pRT-PCR.

39 **Results:** Blastocyst yield was lower ($p < 0.05$) in BSA groups compared to dFCS groups.
40 Survival rates after vitrification/warming were improved in dFCS-EVs compared to
41 dFCS ($p < 0.05$). EVs increased ($p < 0.05$) blastocysts total cell number in dFCS-EV and
42 BSA-EV compared to dFCS and BSA groups, while lipid content was decreased and
43 mitochondrial activity increased in dFCS-EV ($p < 0.05$). Lipid metabolism transcripts
44 were affected by EVs (*PPARGC1B* and *ACACA*, $p < 0.05$) and protein source in the
45 medium (*CD36*, *PLIN2* and *ATGL*, $p < 0.05$). Levels of pHSL were lower in dFCS
46 ($p < 0.05$). Twenty miRNA were differentially expressed between OF- and UF-EVs and
47 only bta-miR-148b was increased in OF-EVs ($p < 0.05$).

48 **Conclusions:** Mimicking physiological conditions using EVs from OF and UF in
49 sequential IVC does not affect embryo development but improves blastocyst quality
50 regarding survival rate after vitrification/warming, total cell number, lipid content,
51 mitochondrial activity and relative changes in expression of lipid metabolism transcripts
52 and lipase activation. Besides, EVs miRNA contents may contribute to the observed
53 effects.

54 **Keywords:** exosomes, miRNAs, embryo development, cryopreservation, lipid
55 metabolism, oviduct, uterus, cattle.

56 **Introduction**

57 In vitro production (IVP) of bovine embryos is applied to animal breeding programs to
58 enhance reproductive efficiency and genetic gain, and has been widely used in many
59 countries for commercial and research purposes [1]. However, there is still the need for
60 improvements, particularly regarding embryo quality in comparison to in vivo derived
61 (IVD) embryos [2–4]. This lower quality is observed in terms of their reduced
62 cryotolerance [5], altered gene expression [3,6], metabolism [7,8], morphology [9] and
63 developmental kinetics [10]. Also, lower pregnancy rates are observed [11], which can
64 be related to long-lasting effects of in vitro culture (IVC) resulting in various failures in
65 post-transfer development up to and after calving [12]. IVP embryos when exposed to
66 in vivo conditions improve quality, which is further increased with longer times of
67 exposure [13]. Besides, modifications to the post-fertilization IVC conditions can
68 improve blastocyst quality [5]. Therefore, improvements to the IVC system are still
69 necessary to obtain IVP embryos of better quality for higher pregnancy rates and
70 healthy offspring births, the ultimate outcome for efficient IVP systems.

71 Among the reasons for lower quality and cryotolerance, is the higher lipid contents of
72 IVP embryos compared to IVD [2,14]. When lipid contents are reduced by different
73 means, improved cryotolerance has been reported [15–18]. One of the factors
74 implicated with higher lipid accumulation in IVP embryos has been the use of serum
75 during IVC [19–22]. Fetal calf serum (FCS) is a common supplement in IVC. Although
76 it has been related to reduced embryonic quality, it paradoxically stimulates embryo
77 development [20]. Serum-free embryo culture is possible, but an altered expression of
78 lipid metabolism genes has been reported. Therefore, such conditions still need to be
79 optimized [23].

80 Amidst strategies used to improve embryo development in vitro, are efforts to mimic
81 the physiological conditions observed in vivo. Preimplantation embryo development in
82 vivo initiates within the oviduct, where the embryo will remain for about four days, and
83 then will enter the uterus [24]. During this period, the embryo will develop mostly
84 dependent on nutrients present in oviductal (OF) and uterine fluid (UF), until
85 implantation around Day 20 [25]. The importance of components supplied by the
86 female reproductive tract to the developing embryo, especially during early
87 development, has been highlighted (reviewed by [26,27]). Previous studies have shown
88 that the use of medium conditioned by bovine oviduct epithelial cells (BOECs) [28] or
89 supplemented with low concentrations of OF in IVC medium [29] improve quality and
90 cryotolerance of IVP embryos. Less is known relative to the use of UF in vitro.

91 However, embryo quality was also enhanced when the IVC medium was supplemented
92 with a low concentration of OF during the initial four days, followed by a sequential
93 culture with a low concentration of UF up to the blastocyst stage until Day 9 [30].

94 Extracellular vesicles (EVs) are present in both fluid types, and may be involved, at
95 least in part, in the positive effects reported when these fluids are added during IVC.

96 EVs are membranous vesicles secreted by many cell types and identified in several
97 body fluids, containing diverse substances (proteins, lipids, metabolites and nucleic
98 acids, including miRNAs), and are considered a cell signalling system, involved in
99 various physiological and pathological processes (reviewed by [31,32]). EVs can be
100 classified according to their size in two types: the small EVs (smaller than 200 nm) and
101 the large EVs (bigger than 200 nm) [33]. In the female reproductive system, EVs have
102 been found in several species (reviewed by [34,35]), including fluids from bovine
103 oviduct [36,37] and uterus [38,39]. Supplementation of IVC medium with EVs isolated
104 either from BOECs conditioned medium [28] or from OF [36,37], showed positive
105 effects on embryo development and quality. EVs isolated from bovine UF also favoured
106 the development and quality of somatic cell nuclear transfer bovine embryos [39].
107 Additionally, EVs from BOECs conditioned medium had positive effects on embryo
108 quality in terms of cryotolerance, even in the presence of serum [28]. This improvement
109 could be related to lower lipid contents in such embryos, but this parameter was not
110 assessed in this study. Interestingly, Almiñana et al. [37] recently detected the
111 lipogenesis enzyme fatty acid synthase (FASN) among mRNAs in EVs from bovine
112 OF, besides other mRNAs and microRNAs (miRNAs, small non-coding RNAs acting in
113 post-transcriptional regulation, [40]) related with lipid metabolism, which could
114 potentially affect lipid metabolism in embryos exposed to these EVs.

115 In the present study, we have investigated the effects of EVs from OF and UF, when
116 supplemented to IVC medium in a sequential culture system. We hypothesized that this
117 supplementation could improve embryo development and quality, and affect the lipid
118 contents and expression of lipid metabolism-related genes in IVP embryos. The miRNA
119 contents of these EVs were investigated as well. New knowledge in this field could

120 provide the basis for the development of better culture systems, which could bring
121 improvements to the quality of in vitro produced embryos.

122 **Materials and Methods**

123 **Experimental design**

124 The developmental capacity of bovine zygotes and the quality of the produced
125 blastocysts cultured in vitro with EVs from OF and UF, mimicking the physiological
126 preimplantation environment in vivo was assessed. At approximately 20 h after
127 insemination, presumptive zygotes were cultured in 4 groups: (i) BSA: SOF with 3
128 mg/mL BSA; (ii) dFCS: SOF with 5% dFCS; (iii) BSA-EV: SOF with 3 mg/mL BSA
129 supplemented with 3×10^5 EVs/mL from OF (D1 to D4) and 3×10^5 EVs/mL from UF
130 (D4 to D9); and (iv) dFCS-EV: SOF with 5 % dFCS supplemented with 3×10^5 EVs/mL
131 from OF (D1 to D4) and 3×10^5 EVs/mL from UF (D4 to D9). BSA and dFCS groups
132 underwent media renewal on Day 4 (Figure 1). Blastocyst development was assessed on
133 Days 7, 8 and 9. To assess blastocyst quality a representative number of Days 7–8
134 blastocysts from each group were either vitrified/warmed, and survival rate was
135 recorded every 24 hours up to 72 hours after warming or fixed and stained for
136 mitochondrial activity, lipid content and total cell number analysis. In addition, Day 7–8
137 blastocysts were frozen in liquid nitrogen in groups of 10 and stored at -80°C for gene
138 expression or western blot for protein analyses. miRNA contents in EVs were analysed
139 as well.

140 **Materials**

141 Unless otherwise stated, all chemicals were purchased from Sigma-Aldrich Corporation
142 (St Louis, MO, USA).

143 **Isolation and characterization of small Extracellular Vesicles (EVs)**

144 Isolation and characterization of EVs from bovine oviduct and uterine fluids analysis
145 was performed according to Cañón-Beltrán et al. [41], with minor modifications.

146 **Oviductal and uterine flushing for EVs isolation**

147 Five oviducts and five uteri from slaughtered heifers were selected according to the
148 stage of the corpus luteum, and transported to the laboratory on ice. Only oviducts
149 corresponding to Stage 1 (from Day 1 to Day 4 of the estrous cycle) and uteri to Stage 2
150 (from Day 5 to Day 10; [42]) ipsilateral to the corpus luteum were used. Each oviduct
151 and the corresponding uterine horn was trimmed free of associated tissues and washed
152 in cold Ca^{2+} and Mg^{2+} -free phosphate-buffered saline (PBS^-). Then, each oviduct was
153 flushed with 1 mL cold PBS^- from ampulla to isthmus while each uterine horn was
154 flushed with 2.2 mL cold PBS^- towards the uterine tubal junction. During all processes
155 the temperature was maintained at 4 °C. Each oviduct and uterine flush sample was
156 recovered and centrifuged once at 300 g for 7 min to remove cells, then the supernatant
157 from each sample was centrifuged again at 10,000 g for 30 min at 4 °C to remove
158 cellular debris [43]. The resulting supernatants were each separately passed through a
159 0.22 μm filter and stored at 4 °C until EVs isolation the next day.

160 **Small extracellular vesicle isolation by Size Exclusion Chromatography**

161 OF-EVs and UF-EVs were isolated by size exclusion chromatography (SEC), according
162 to manufacturer's instructions (Pure EVs®, HBM-PEV; Hansa BioMed Life Sciences).
163 Briefly, columns were firstly washed with 30 mL PBS^- and then each OF (≈ 1 mL) or
164 UF (≈ 2 mL) sample was loaded onto the top of a SEC column, and when the sample
165 was completely within the column, 11 mL PBS^- were loaded. Immediately, the first 3.0
166 mL were discarded and the following 2.0 mL of EVs-rich fractions were collected.
167 Next, the 2.0 mL samples containing EVs were submitted to ultracentrifugation (UC) at

168 100,000 g for 1 h at 4 °C using an Optima L-90K ultracentrifuge (Beckman Coulter,
169 Fullerton, CA, USA) and a swinging-bucket rotor (SW 41 Ti). Supernatants were then
170 discarded and each pellet was suspended in 100 µL cold PBS. Thirty microliters were
171 taken from each of the five EVs suspensions of OF and UF and pooled, from which part
172 was frozen at -20 °C to be used in IVC (100 µL EVs suspension from OF and 100 µL
173 from UF) and 5 µL were used for characterization by nanoparticle tracking analysis
174 (NTA) and 5 µL for transmission electron microscopy (TEM). From the remaining
175 volume of the original five EVs samples (Stage 1 OF and Stage 2 UF), 70 µL were used
176 for miRNA analysis. Another ten samples of EVs from Stage 1 OF and from Stage 2 UF
177 were collected and isolated in the same way and their EVs suspensions were entirely
178 used for western blot analysis.

179 **EVs characterization**

180 **Nanoparticle tracking analysis (NTA)**

181 Analysis of absolute size distribution of EVs was performed using a NanoSight LM-10
182 system equipped with a CCD video camera and particle-tracking software NTA 3.1
183 Build 3.1.45 (NanoSight Ltd., Minton Park, UK). With NTA, particles are automatically
184 tracked and sized based on Brownian motion and the diffusion coefficient. After
185 isolation, 5 µL of EVs solution were diluted in 95 µL of filtered PBS⁻. The NTA
186 measurement conditions were detection threshold 2 to 3, camera level 13,
187 temperature 22 °C and measurement time 60 s. Three recordings were performed for
188 each sample. After EVs concentration of each sample was determined, the samples were
189 diluted to a standardized concentration (3×10^5 particles/mL, [28,36]), aliquoted and
190 stored frozen at -20 °C for later use in embryo culture experiments.

191 **Transmission electron microscopy (TEM)**

192 Five microliters of each EVs suspension were diluted in 45 μ L. Next, the 25 μ L of EVs
193 preparations were allowed to adsorb onto Formvar/carbon-coated 200 mesh copper
194 grids (Agar Scientific, Essex, UK) for 1 min at room temperature. Grids were then
195 washed twice with distilled water. For negative staining, grids were transferred to a 50
196 μ L droplet of 2% uranyl acetate for 20 seconds, followed by blotting the excess liquid.
197 Grids were air-dried and TEM visualizations were performed at the National Center for
198 Electron Microscopy of the Universidad Complutense de Madrid (ICTS-CNME-UCM)
199 using a JEOL JEM1010 (100kV) transmission electron microscope (Jeol Ltd., Tokyo,
200 Japan) equipped with a Megaview II CCD camera integrated into iTEM Olympus Soft
201 Imaging Solutions software (Olympus, Tokyo, Japan).

202 **Western blot for EV marker proteins**

203 EVs preparations were lysed in 1 \times RIPA buffer (Cell Signaling Technology, 9806S),
204 supplemented with 1 \times protease, phosphatase Inhibitor Cocktail (Roche, Basel,
205 Switzerland). Protein concentrations in the EVs samples were determined by the
206 Bicinchoninic acid assay (BCA) (Micro BCA Protein Assay Kit; 23325). A total of 35
207 μ g of protein per sample was suspended in Laemmli loading buffer, then loaded and
208 separated in a 4–12% gradient SDS-PAGE polyacrylamide gel. Proteins were
209 transferred onto nitrocellulose membranes (GE Healthcare Life Sciences WhatmanTM).
210 The membranes were washed in distilled water and blocked with 3% bovine serum
211 albumin (BSA) in PBS-T (PBS+0.1% Tween-20) for 30 min at room temperature. The
212 membranes were incubated with primary antibodies diluted in PBS-T supplemented
213 with 3% BSA overnight at 4 $^{\circ}$ C with gentle shaking. Three primary antibodies were
214 used as EVs biomarkers and one as negative control: anti-tetraspanin cell surface
215 protein CD9 antigen (1:1000, anti-CD9 mAb, 13403, Cell Signaling Technology,
216 D3H4P, Danvers, MA, USA), anti-heat shock protein 70 (1:1000, anti-HSP70 mAb,

217 C92F3A-5, Enzo Life Sciences, NY, USA); anti-ALG-2-interacting protein X protein
218 (1:1000, anti-ALIX mAb, sc-53540, Santa Cruz Biotechnology, CA, USA). As
219 negative control, anti-Calnexin (1:1000, anti-CANX mAb sc-23954, Santa Cruz
220 Biotechnology, CA, USA) was used to indicate the absence of cell contamination in
221 EVs samples. After primary antibodies incubation, the membranes were washed with
222 PBS-T and incubated for 2 hours under agitation with secondary antibodies. The
223 following horseradish peroxidase (HRP) conjugated secondary antibodies were used:
224 goat anti-rabbit IgG-HRP (1:5000, 7074S, Cell Signaling Technology, Danvers, MA,
225 USA) or horse anti-mouse IgG-HRP (1:5000, 7076S, Cell Signaling Technology,
226 Danvers, MA, USA). The membranes were again washed three times in PBS-T for 5
227 min and incubated for 1 min in the Immobilon Forte Western HRP substrate
228 (#WBLUF0100, Millipore, Burlington, MA, USA) and revealed by chemiluminescence
229 with an Image Quant LAS500 biomolecular imager (GE Healthcare Life Sciences,
230 USA, 29005063). The blood, pancreas, lungs and ureters tissues of mice were used as
231 positive controls for the proteins CD9, HSP70, ALIX and CANX where they are
232 respectively highly expressed.

233 **EVs miRNA contents analysis**

234 **EVs RNA extraction**

235 Total RNA (including small RNAs) was extracted (n=3 per group) using the miRNeasy
236 Mini Kit (217004, Qiagen, Venlo & Limburg, the Netherlands) according to
237 manufacturer's instructions. RNA concentration and quality were evaluated by
238 NanoDropTM (Thermo Scientific) and samples with the highest RNA amount were used
239 for analysis.

240 **miRNAs analysis**

241 Analysis of miRNA contents was performed as described by Da Silveira et al. [44], with
242 minimal modifications. Briefly, reverse transcription was conducted on the total RNA
243 (120 ng/sample) using the miScript PCR System (Qiagen, Venlo & Limburg, the
244 Netherlands) according to the manufacturer's instructions. Briefly, total RNA, including
245 small RNA fraction, were incubated with 5x miScript Hiflex Buffer, 10x miScript
246 Nuclei mix, RNase free water, and miScript reverse transcriptase at 37 °C for 60 min,
247 followed by 5 min at 95 °C. The relative abundance levels of 383 mature miRNAs were
248 established via quantitative real-time (qRT-PCR), using the miSCRIPT II RT kit
249 (Qiagen, Venlo & Limburg, the Netherlands), according to manufacturer's instructions.
250 Reactions were prepared in 6 µL master mix containing 2x QuantiTect SYBER Green
251 PCR Master Mix (Qiagen), 10x miScript Universal Primer, miRNA specific forward
252 primers and 0.024 µL of 1:4 diluted cDNA. qRT-PCR was conducted in a 384-well
253 plate using the Quantstudio 6 System (Applied Biosystems). The PCR cycling
254 conditions were 95 °C for 15 min, 45 cycles of 94 °C for 10 s, 55 °C for 30 s, and 70 °C
255 for 30 s followed by a melting curve analysis to confirm the specificity of cDNA
256 amplification. To quantify miRNAs expression level in EVs isolated from OF and UF,
257 raw cycle threshold (Ct) values were normalized to the geometric mean of bta-miR-99b,
258 Hm/Ms/Rt T1 snRNA and RNT43 snoRNA, as internal controls. OF and UF-EVs
259 samples were analysed in triplicate, and only miRNAs with a Ct value less than 37, and
260 detected in at least two of the three samples in each group, were considered to be
261 present.

262 **In vitro embryo production**

263 **EVs depletion of FCS for use in IVC experiments**

264 To produce foetal calf serum (FCS) depleted from its EVs (dFCS), heat-inactivated FCS
265 was ultra-centrifuged at 100,000 for 18 hours at 4 °C using an Optima-L-100XP

266 Beckman Coulter ultracentrifuge. Under a laminal hood the supernatant (dFCS) was
267 collected, aliquoted and stored at -20 °C for later use in embryo culture. The same batch
268 was used in the entire experiment.

269 **Oocyte collection and in vitro maturation**

270 Immature cumulus-oocyte complexes (COCs) were obtained by aspirating follicles (2–8
271 mm) from the ovaries of mature heifers and cows collected from local abattoirs. COCs
272 were selected and matured in four-well dishes (Nunc, Roskilde, Denmark) in 500 µL
273 TCM-199 medium supplemented with 10% (v/v) FCS and 10 ng/mL epidermal growth
274 factor (EGF), in groups of 50 COCs per well, for 24 hours at 38.5 °C and under an
275 atmosphere of 5% CO₂ in air with maximum humidity.

276 **Sperm preparation and in vitro fertilization (IVF)**

277 IVF was performed as described previously [36]. Briefly, frozen semen straws (0.25
278 mL) from an Asturian Valley bull previously tested for IVF were thawed at 37 °C in a
279 water bath for 1 min and sperm cells were selected on a gradient of Bovipure (Nidacon
280 Laboratories AB, Göthenborg, Sweden). Sperm concentration was determined and
281 adjusted to a final concentration of 1×10^6 sperm cells/mL. Gametes were coincubated
282 for 18-22 hours in 500 µL fertilization medium (Tyrode's medium with 25 mM
283 bicarbonate, 22 mM sodium lactate, 1 mM sodium pyruvate and 6 mg/mL fatty acid-
284 free BSA) supplemented with 10 µg/mL heparin sodium salt (Calbiochem, San Diego,
285 CA, USA) in a four-well dish, in groups of 50 COCs per well, under an atmosphere of
286 5% CO₂ with maximum humidity at 38.5 °C.

287 **In vitro culture of presumptive zygotes**

288 At approximately 18-22 hours post-insemination (hpi), presumptive zygotes were
289 denuded of cumulus cells by vortexing for 3 min and then cultured in groups of 20-25
290 zygotes in 25 μ L droplets of culture medium (synthetic oviductal fluid, (SOF); [45] with
291 4.2 mM sodium lactate, 0.73 mM sodium pyruvate, 30 μ L/mL basal medium eagle
292 (BME) amino acids, 10 μ L/mL minimum essential medium (MEM) amino acids and 1
293 μ g/mL phenol-red). Embryos were cultured in medium that was supplemented with 3
294 mg/mL BSA or 5% dFCS in the presence (BSA-EV and dFCS-EV) or absence (BSA
295 and dFCS) of 3×10^5 EVs/mL from OF (D1 to D4) and UF (D5 to D9), under mineral oil
296 at 38.5 °C and an atmosphere of 5% CO₂, 5% O₂ and 90% N₂. BSA was included as an
297 additional comparison group as it has been shown to improve embryo quality and
298 cryotolerance [30,36].

299 **Assessment of embryo EVs uptake, development and quality**

300 **EVs uptake by embryos**

301 EVs isolated from OF and UF were labelled with a lipophilic green fluorescent dye
302 (PKH67, Sigma, USA) as described by Almiñana et al. [37] with some modifications.
303 Firstly, 25 μ L of the EVs suspension in PBS were mixed with 125 μ L of diluent C (Cell
304 mixture) and for the negative control, 25 μ L of PBS⁻ without EVs were also mixed with
305 125 μ L of diluent C. Next, the dye was diluted in diluent C (1:250), and each sample
306 (EVs and controls) was then placed into 125 μ L of the dye mix and incubated for 5 min
307 at room temperature (final concentration of dye is 5×10^{-6} M). To stop the labelling
308 reaction 250 μ L per sample of 1% BSA in PBS⁻ was added for 1min. The samples (dye-
309 EVs and dye-PBS⁻ negative control) were washed four times (three 15 min
310 centrifugations at 2,000 g and one for 20 min) with 9 mL PBS⁻ in Amicon Vivaspin®
311 filters (Sartrius Stedim, Germany). The samples (100 μ L) were then filtered with a 0.22

312 μm filter and diluted 1:1 with SOF medium (2x) without phenol red and with BSA 3
313 mg/mL (final concentration), and the embryos were cultured in this medium. The
314 labelled EVs from OF and the PBS⁻ negative control (labelled but without EVs) were
315 used in the culture of D3 8-cell embryos for 5 hours, and the labelled EVs from UF and
316 the PBS⁻ negative control (labelled but without EVs) were used in the culture of D8
317 blastocysts also for 5 hours. After the culture period, embryos were then collected and
318 washed twice in PBS to remove any labelled vesicles that were not internalized,
319 followed by fixation in 4% paraformaldehyde (PF) during 30 minutes, washing, and
320 labelling with Hoechst 33342. Finally, embryos (10-14 per group) were placed in a
321 droplet of ProLong Diamond Antifade Mountant on a glass slide, covered with a
322 coverslip, and then analysed under a multispectral confocal microscope (Leica TCS-SP8
323 STED 3X) using the 63X objective.

324 **Embryo development**

325 Cleavage rate was recorded on Day 2 (48 hpi) and cumulative blastocyst yield was
326 recorded on Days 7, 8 and 9 pi.

327 **Embryo quality**

328 **Blastocyst vitrification**

329 The ability of the blastocyst to withstand cryopreservation was used as an indicator of
330 quality. Day 7–8 blastocysts from each treatment (N=67, 52, 86 and 64 for BSA, BSA-
331 EV, dFCS and dFCS-EV, respectively) were vitrified in holding medium (HM),
332 consisting of TCM 199 supplemented with 20% (v/v) FCS, and cryoprotectants as
333 described previously [2] in a two-step protocol using the Cryoloop device (Hampton
334 Research, Aliso Viejo, CA, USA). In the first step, HM was supplemented with 7.5%
335 ethylene glycol and 7.5% dimethyl sulfoxide; in the second step, HM was supplemented

336 with 16.5% ethylene glycol, 16.5% dimethyl sulfoxide and 0.5 M sucrose. Blastocysts
337 were warmed in two steps in HM with 0.25 and 0.15 M sucrose and then cultured in 25-
338 mL droplets of SOF with 5% FCS. Survival was defined as re-expansion of the
339 blastocoel and its maintenance for 72 hours after warming.

340 **Mitochondrial activity measurement, lipid content quantification and total cell**
341 **number in blastocysts**

342 For mitochondrial activity, blastocysts (D7-8) from each treatment (N=29, 29, 33 and
343 27 for BSA, BSA-EV, dFCS and dFCS-EV, respectively) were first suspended in 100
344 μ L PBS without calcium and magnesium supplemented with 0.1% polyvinylpyrrolidone
345 (PVP). Next, blastocysts were equilibrated for 15 minutes in culture medium
346 supplemented with 5% FCS and then incubated for 30 minutes at 38.5 °C in 400
347 nM/mL MitoTracker DeepRed (Molecular Probes, Eugene, USA); blastocysts were then
348 fixed in 4% PF for 30 min at room temperature. For lipid content analysis (N=28, 26, 25
349 and 29 for BSA, BSA-EV, dFCS and dFCS-EV, respectively), the blastocysts were
350 fixed in PF and then permeabilized with 0.1% saponin for 30 min and stained for 1 hour
351 with 20 μ g/mL Bodipy 493/503. For total cell number the blastocysts (N=57, 55, 58 and
352 56 for BSA, BSA-EV, dFCS and dFCS-EV, respectively) were stained with Ho \ddot{e} chst
353 33342 (10 μ g/mL) for 30 min, after being stained either for mitochondria or for lipids.
354 After each stain the blastocysts were washed in PBS+0.1% PVP three times for 5
355 minutes each. Finally, blastocysts were mounted in 3.8 μ L mounting medium (ProLong
356 Gold, Thermo Fisher Scientific) between a coverslip and a glass slide and sealed with
357 nail polish.

358 Slides were examined using a laser-scanning confocal microscope (Leica TCS SP2)
359 equipped with an argon laser excited at 488 nm and whose emission spectrum is 500-
360 537 nm for visualization of lipid droplets. For mitochondria, excitation and emission

361 were set at 543 nm and 580– 650 nm, respectively. The format, laser, gain and offset
362 were kept constant for every sample.

363 For the assessment of mitochondrial activity, the fluorescence signal intensity (pixels)
364 was quantified. Serial sections of 5 μm were made for each blastocyst and a maximum
365 projection was accomplished for each one. Images obtained were evaluated using the
366 ImageJ program (NIH; <http://rsb.info.nih.gov/ij/>). After selection using the freehand
367 selection tool, each blastocyst was measured to determine its area and its integrated
368 density (IntDen), which corresponds to pixel intensity. In addition, the background
369 fluorescence of an area outside the blastocyst was measured. Fluorescence intensity in
370 each blastocyst was determined using the following formula: Relative fluorescence =
371 IntDen - (area of selected blastocyst x mean fluorescence of background readings).

372 Fluorescence intensities are expressed in arbitrary units (a.u.) [46]

373 The lipid quantity in blastocysts was obtained by analysis of the total area of lipids in
374 each embryo. We captured three images of each blastocyst: one in the middle of the
375 blastocyst (the image with the largest diameter) and the other two in the middle of the
376 resulting halves. We used a 63X objective at a resolution of 1024 x 1024 and images
377 were analysed using the ‘nucleus counter’ tool, set to detect, distinguish and quantify
378 droplet areas with the ImageJ software (NIH, USA) and expressed as the area of lipid
379 droplets relative to the total area of the blastocyst without its cavity (μm^2). For
380 blastocysts, lipid quantity was corrected by area, to account for varying blastocyst sizes.
381 After verification of a significant correlation ($r^2 = 0.84$ and $P < 0.0001$ by Pearson’s
382 correlation test) between lipid quantity of three sections in 30 blastocysts (10 per group)
383 we chose the section with the largest area per embryo to be analysed [22]. The number
384 of cells per blastocyst was determined by counting the Hoechst-stained cells under an

385 epifluorescence microscope (Nikon 141731) equipped with a fluorescent lamp (Nikon
386 HB-10104AF) and UV-1 filter.

387 **Gene expression analysis**

388 Gene expression analysis was performed using Day 7–8 blastocysts (pools of 10 in three
389 replicates per treatment). All samples were washed in PBS, snap-frozen in LN₂ and
390 stored at -80 °C until mRNA extraction analyses. Poly(A) RNA was extracted using the
391 Dynabeads mRNA Direct Extraction Kit (Ambion; Thermo Fisher Scientific) with
392 minor modifications [47]. Immediately after poly(A) RNA extraction, reverse
393 transcription (RT) was performed using a MMLV Reverse Transcriptase 1st-Strand
394 cDNA Synthesis Kit according to the manufacturer's instructions (Epicentre
395 Technologies). Poly(T) random primers and Moloney murine leukaemia virus (MMLV)
396 high-performance reverse transcriptase enzyme were used in a total volume of 40 µL to
397 prime the RT reaction and to produce cDNA. Tubes were heated to 70 °C for 5 min to
398 denature the secondary RNA structure and the RT mix was then completed by adding
399 50 units of reverse transcriptase. Samples were incubated at 25 °C for 10 min, to help
400 the annealing of random primers, followed by incubation at 37 °C for 60 min, to allow
401 the RT of RNA, and finally at 85 °C for 5 min to denature the enzyme. All mRNA
402 transcripts were quantified in duplicate using a Rotorgene 6000 Real Time Cycler
403 (Corbett Research). RT–quantitative polymerase chain reaction (qPCR) was performed
404 by adding 2 µL aliquot of each cDNA sample (~60 ng µL⁻¹) to the PCR mix (GoTaq
405 qPCR Master Mix, Promega) containing the specific primers to amplify transcripts for
406 the genes (Additional file 1: Table S1). The selection of genes to be evaluated was
407 carried out considering the expression of key genes in lipid metabolism. All primers
408 were designed using Primer-BLAST software

409 (<http://www.ncbi.nlm.nih.gov/tools/primer-blast/>) to span exon–exon boundaries when
410 possible. For quantification, RT-qPCR was performed as described previously [48]. The
411 PCR conditions were tested to achieve efficiencies close to 1. Relative expression levels
412 were quantified by the comparative cycle threshold (CT) method [49]. Values were
413 normalized using two housekeeping (HK) genes: H2AZ1 and ACTB (Additional file 1:
414 Table S1). Fluorescence was acquired in each cycle to determine the threshold cycle or
415 the cycle during the log-linear phase of the reaction at which fluorescence increased
416 above the background for each sample. Within this region of the amplification curve, a
417 difference of one cycle is equivalent to a doubling of the amplified PCR product.
418 According to the comparative CT method, the Δ CT value was determined by
419 subtracting the mean CT value of the two HK genes from the CT value of the gene of
420 interest in the same sample. The calculation of $\Delta\Delta$ CT involved using the highest
421 treatment Δ CT value (i.e. the treatment with the lowest target expression) as an arbitrary
422 constant to subtract from all other Δ CT sample values. Fold-changes in the relative gene
423 expression of the target were determined using the formula $2^{-\Delta\Delta$ CT}.

424 **Protein analysis in blastocysts**

425 Protein analysis was performed using Day 7–8 blastocysts (pools of 20 in 3 replicates
426 per treatment). Embryo samples were lysed in RIPA buffer supplemented with 1×
427 protease, phosphatase Inhibitor Cocktail. Proteins were resolved in SDS-PAGE (4–12%
428 acrylamide gel loading 45 μ L of total protein per well) and transferred to a
429 nitrocellulose membrane (Amersham™ Protran™ 0.45 NC), blocked with 3% BSA in
430 PBS-T and incubated overnight at 4 °C with the following primary antibodies: HSL
431 rabbit (1:1000 in 3% BSA + 0.1% PBS-T, #4107S, Cell Signaling Technology, Boston,
432 MA, USA), pHSL rabbit (phospho-HSL, 1:1000 in 3% BSA + 0.1% PBS-T, #4139S,
433 Cell Signaling Technology, Boston, MA, USA). The membranes were washed three

434 times in 1X TBS-T for 5 min and incubated for 2 hours at room temperature with a goat
435 anti-rabbit IgG-HRP (1:5000 in 1% BSA + 0.1% PBS-T, #7074, Cell Signaling
436 Technology, Danvers, MA, USA). The membranes were again washed three times in
437 1X TBS-T for 5 min and incubated for 5 min in Enhanced Chemiluminescence kit
438 (RPN2109, ECLTM, Amersham GE Healthcare, Buckinghamshire, UK) and detected by
439 an ImageQuant LAS 500 chemiluminescence CCD camera (GE Healthcare Life
440 Sciences, USA, 29005063).

441 The monoclonal anti- β -actin-peroxidase antibody produced in mouse (Merk,
442 Darmstadt, Germany, A3854) was used as the loading control. For this purpose, after
443 the chemiluminescent detection of HSL and pHSL, membranes were stripped and then
444 wash extensively in TBS-T and repeating the blocking step, the membrane is re-probed
445 with an anti-actin antibody. In all cases, intensities of protein bands [(optical density
446 (OD))] were quantified by ImageJ software and normalized relative to the abundance of
447 actin in each lane and phosphorylation level was expressed as phosphorylated
448 pHSL/HSL. The ratio of the OD of the protein concerned (HSL/pHSL) in relation to
449 actin is presented in the form of bar charts [41].

450 **Statistical analysis**

451 Cleavage and blastocyst rates, and vitrification data were analysed by *Chi*-square test.
452 Number of cells per blastocyst, relative mRNA abundance and protein level
453 (pHSL/HSL) were normally distributed with homogeneous variance, so one-way
454 analysis of variance (ANOVA) followed by Tukey's test was performed to evaluate the
455 significance of differences between groups. For mitochondrial activity and lipid content,
456 data were analysed by Kruskal-Wallis followed by Dunn's pairwise multiple
457 comparisons test. The correlation analysis for lipid quantification in blastocyst was

458 determined by linear regression r^2 test and significance of the correlation by F test.
459 Values were considered significantly different at $P < 0.05$. Unless otherwise indicated,
460 data are presented as the mean \pm s.e.m. All analyses were made with the SigmaStat
461 software package (Jandel Scientific, San Rafael, CA). For miRNA, data were displayed
462 as the mean \pm SD of replicate samples. Statistical analyses were performed using SAS
463 9.3 Software (SAS Institute). A Student's t-test was used to assess statistical
464 differences, and normality was verified using a Shapiro–Wilk test, where a statistical
465 difference of 5% was considered to be significant.

466 **Results**

467 **OF and UF EVs characterization**

468 **NTA**

469 This analysis was performed to characterize the size and concentration of particles
470 present in the pools of the five samples isolated from OF and UF. NTA showed that
471 concentration in OF was 2.97×10^{10} particles/mL, while the mean size was 177.5 nm
472 and modal size 137.2 nm. In UF concentration was 7.98×10^{10} particles/mL and mean
473 and modal sizes were 216.5 and 151.2, respectively. Concentration/Size distribution of
474 EVs from oviductal and uterine samples, which were used for IVC experiments, are
475 shown in Figure 2A.

476 **TEM**

477 Figure 2B shows representative images from TEM analysis for the presence and
478 morphology of EVs in oviductal and uterine samples. The structures observed are
479 compatible with EVs, confirming NTA data and their presence in the samples analysed.

480 **Western Blotting**

481 Marker proteins for EVs CD9, HSP70 and ALIX were detected in OF and UF samples
482 (Figure 2C). The negative control CANX was not detected in any samples, except for its
483 positive control tissue (urethra). These observations further confirm the presence of EVs
484 in the samples analysed and the absence of cell contamination.

485 **In vitro culture**

486 **EVs uptake**

487 To confirm that EVs added to the media were taken up by embryos, therefore, would be
488 capable of affecting their development and/or quality, 8-cell embryos (Day 3) and
489 blastocysts (Day 8) were cultured for 5 hours with fluorescently labelled EVs from OF
490 and UF, respectively. As observed in Figure 3, uptake of both types of EVs was
491 confirmed with their presence inside the blastomeres.

492 **Embryo development**

493 As shown in Table 1, cleavage was not affected by treatments ($P>0.05$) and the mean
494 rate was 89.9%. Blastocyst rate on Day 7 of culture, however, showed that groups
495 treated with BSA, with or without EVs (16.2 and 14.1 %, respectively, $P>0.05$), were
496 lower ($P<0.05$) than dFCS groups, with or without EVs (30.5 and 31.1%, respectively,
497 $P>0.05$). On D8, BSA and BSA-EV (31.0 and 26.2%, respectively) still had lower
498 ($P<0.05$) blastocyst rates than dFCS and dFCS-EV (40.7 and 39.8 %, respectively,
499 $P>0.05$), and BSA-EVs had lower development than BSA ($P<0.05$). The same pattern
500 was seen on D9, where BSA and BSA-EV (34.6 and 29.2%, respectively), were lower
501 ($P<0.05$) than dFCS and dFCS-EV (41.7 and 41.4%, respectively, $P>0.05$) and BSA-EV
502 was lower than BSA ($P<0.05$).

503 **Table 1.** Cleavage (D2) and cumulative blastocyst development rates (D7-9) after in vitro
504 culture with BSA or dFCS supplemented or not with OF-EVs (D1-4) and UF-EVs (D5-
505 8) (28 replicates).

Treatment	IVC n	Cleaved		blastocysts		
		D2	D7	D8	D9	
		n (% ± SEM)	n (% ± SEM)	n (% ± SEM)	n (% ± SEM)	
BSA	1584	1427 (89.5±1.0)	248 (16.2±1.5) ^a	484 (31.0±1.9) ^a	548 (34.6±1.7) ^a	
BSA-EV	1853	1677 (89.7±1.1)	261 (14.1±1.7) ^a	496 (26.2±2.0) ^b	555 (29.2±2.1) ^b	
dFCS	1594	1435 (89.5±0.9)	476 (30.5±2.0) ^b	648 (40.7±2.5) ^c	659 (41.7±2.4) ^c	
dFCS-EV	1473	1337 (90.7±0.9)	460 (31.1±2.5) ^b	590 (39.8±2.7) ^c	615 (41.4±2.8) ^c	

506 ^{a,b,c} Values with different superscripts within a column are significantly different (P<0.05).

507

508 **Embryo quality**

509 **Vitrification**

510 As a parameter to assess the quality of embryos produced in the different treatments, the
511 survival rate after vitrification and warming of blastocysts cultured up to 72 hours in
512 SOF with 5% dFCS was measured (Table 2). Survival rate at 72 hours was highest for
513 dFCS-EV (87.8%, P<0.05) compared to its respective control (dFCS = 69.2%)
514 demonstrating that the presence of EVs improved blastocyst quality. The other groups
515 were similar among themselves with high survival at this time point ranging from 67.1
516 to 73.1% (P>0.05).

517 **Table 2.** Survival rates after vitrification and warming of Day 7-8 blastocysts cultured
518 with BSA or dFCS supplemented or not with OF-EVs (D1-4) and UF-EVs (D5-8).

Treatment	IVC n	4h n	24h n	48h n	72h n
-----------	----------	---------	----------	----------	----------

		(% ± SEM)	(% ± SEM)	(% ± SEM)	(% ± SEM)
BSA	67	64	56	51	49
		(95.4±2.8)	(78.5±6.6)	(68.6±8.9)	(67.1±8.1) ^a
BSA-EV	52	48	43	41	39
		(93.9±6.1)	(84.2±8.7)	(79.2±9.8)	(73.1±10.7) ^a
dFCS	86	80	75	67	61
		(93.4±2.6)	(86.6±4.0)	(75.8±5.7)	(69.2±5.8) ^a
dFCS-EV	64	63	60	57	54
		(97.9±2.1)	(93.3±4.1)	(91.2±4.3)	(87.8±5.7) ^b

519 ^{a,b} Values with different superscripts within a column are significantly different (P<0.05).

520 **Total cell number, mitochondrial activity and lipid contents**

521 Results for total cell numbers in Figure 4 show that although there was no variation in
522 terms of blastocyst production by adding EVs to culture medium, the total nuclei in
523 blastocysts showed differences among treatments.

524 Both groups with EVs did not differ between themselves (BSA-EV = 137.1 ± 3.2 and
525 dFCS-EV = 143.5 ± 3.6, P>0.05), but had increased cell numbers (P<0.05) compared to
526 their respective controls (128.8 ± 2.5 and 124.6 ± 3.5 for BSA and dFCS, respectively),
527 which were also not different (P>0.05). Therefore, the presence of EVs during embryo
528 cultured showed a positive effect, irrespective of the type of protein supplementation
529 used.

530 Regarding mitochondrial activity (Figure 5), EVs supplementation did not affect
531 embryos relative to its respective control for BSA-EV in comparison with BSA,
532 (P>0.05), but for dFCS-EV there was an increase in mitochondrial activity compared to
533 all other groups (P<0.05).

534 Finally, regarding lipid contents (Figure 6), the group cultured with dFCS associated
535 with EVs showed reduction (dFCS-EV = 0.277 ± 0.03 lipid droplet area in μm²,

536 P<0.05) compared to its control (dFCS=0.466 ± 0.02 μm²) and to BSA-EV (0.377 ±
537 0.02 μm²) and was lower but not different from BSA (0.374 ± 0.02 μm²). Thus, in
538 embryos cultured with dFCS, the presence of EVs caused a reduction in lipid contents,
539 while in those cultured with BSA, the addition of EVs had no effect.

540 **Gene expression**

541 As seen in Figure 7, analyses have shown that there was variation in transcripts
542 abundance regarding the presence of EVs, where *PPARGC1B* increased and *ACACA*
543 reduced (P<0.05) in embryos cultured with the vesicles in both media. Regarding *CD36*,
544 *PLIN2* and *PNPLA2*, however, there was an effect by EVs, but it depended on the type
545 of protein supplementation. EVs caused reduction in transcript abundance for *CD36* in
546 BSA-EV compared to its control BSA (P<0.05), while for dFCS-EV there was an
547 increase in this transcript in comparison to its control dFCS (P<0.05). There was a
548 reduction for *PLIN2*, but only in dFCS-EV compared to dFCS (P<0.05), and the same
549 was observed for *PNPLA2*, but in BSA-EV relative to BSA (P<0.05).

550 **Lipolysis proteins**

551 Levels for active (phosphorylated) and total HSL (rate-limiting enzyme for lipolysis)
552 were determined by western blotting in D7-8 blastocysts cultured in medium with BSA,
553 BSA-EV, dFCS and dFCS-EV. As observed in Figure 8, results showed that HSL and
554 pHSL were detected in all groups and that HSL phosphorylation level was significantly
555 lower (P<0.05) in dFCS group compared with all groups.

556 **miRNA in EVs from OF and UF**

557 miRNA contents of EVs in OF and UF were also analysed, and 333 mature miRNAs
558 were detected, from which the twenty most abundant in both fluids are listed in
559 Additional file 2: Table S2. Most of them are common to EVs from both fluids, and the

560 top four are the same (bta-miR-615, bta-miR-323, bta-miR-494 and bta-miR-631) and
561 in a similar order of enrichment, with little variation. Only two were exclusive to OF
562 (bta-miR-493 and bta-let-7a-5p) and two to UF (bta-miR-200c and bta-miR-1225-3p).
563 When the abundance of miRNAs between the two EVs origins was compared, 20 were
564 shown to be significantly differentially expressed ($P < 0.05$), and of these, 19 were more
565 abundant in EVs from UF, while only one was more abundant in EVs from OF (bta-
566 miR-148b, Figure 9).

567 **Discussion**

568 In the present study, we have used a sequential in vitro culture system, by
569 supplementing embryo culture medium with EVs isolated from OF obtained at early
570 luteal phase (Stage 1) and used during the first 4 days in culture, followed by use of
571 EVs isolated from uteri obtained at mid-luteal phase (Stage 2) for the remaining days
572 (up to Day 9). This system intends to mimic the sequence of events undergone by the
573 embryo during its early development in vivo. Besides, EVs have been shown to
574 participate in the communication between embryo and oviduct [37] and uterus [50], and
575 OF and UF as well as EVs isolated from OF and BOECs conditioned medium showed
576 improvements to embryo development and/or quality [29,30,36]. The main findings
577 were that although embryo development was not increased, embryo quality was
578 improved in those cultured with EVs and that lipid metabolism-related genes, as well as
579 an active lipase protein, are affected by their supplementation. Also, the protein source
580 in the medium may influence the functional effects of EVs on bovine embryos produced
581 in vitro.

582 **EVs characterization**

583 Small EVs isolated from OF and UF were characterised by NTA, TEM and WB. The
584 results have shown the expected features for EVs by the three methods, i.e., size,
585 morphology and presence of protein markers. The morphology is the typical cup-shaped
586 seen in TEM as previously described for the bovine oviduct [36,51] and uterus [38,39].
587 The marker proteins for EVs CD9, HSP70 and ALIX [33] were also identified in
588 previous studies in EVs from oviduct (HSP70, [51] and CD9, [36]) and uterus samples
589 (HSP70, [38], CD9, [39]), similar to our observations. Few studies have analysed EVs
590 from bovine oviducts and concentrations found by Almiñana et al. [51] for fluid from
591 Stage 1 oviducts were lower (about 5×10^8 to 1.0×10^9 particles/mL) than the observed
592 in the present study ($\sim 3 \times 10^{10}$ particles/mL). A previous study in our laboratory also
593 with Stage 1 oviducts observed EVs smaller than 200 nm and concentration of 7.5 to
594 10.5×10^8 /mL [36]. The sizes of EVs were not different compared to the other
595 aforementioned studies (<200 nm), but concentrations were higher in ours. These
596 differences are probably due to distinct isolation methods, which can affect particle
597 concentration, purity and size [52].

598 Regarding EVs in bovine UF there is little information available. Only one study also
599 evaluated EVs from Stage 2 uteri and observed that size was mostly between 50-150 nm
600 measured by TEM, but NTA was not performed and concentration was not assessed
601 [39]. In another study using EVs isolated from bovine uteri at different days of
602 pregnancy (17 to 22 days), Kusama et al. [38] also reported sizes of 50-150 nm
603 determined by TEM and 109 to 137 nm by NTA. Particle concentrations were in the
604 order of 10^6 particles/mL, so they were also higher in our study (10^{10} particles/mL), as
605 were sizes (~ 200 nm), and such differences are probably due to the isolation method, as
606 mentioned above. In a recent study from our group we found concentration and size of

607 EVs from OF and UF (30 to 200 nm and 3.4 and 6.0×10^{10} particles/mL, respectively),
608 throughout the estrous cycle [53], similar to the current study.

609 **EVs uptake**

610 Blastocysts cultured with labelled EVs from OF and UF showed presence of fluorescent
611 spots within cytoplasm of blastomeres, confirming that embryos are able to internalize
612 EVs added to culture medium from both origins and at stages of development analysed
613 (from OF in D4 embryos and from UF in D7 blastocysts). Similar observations were
614 also reported in studies using labelled EVs from OF, UF, FF or derived from medium
615 conditioned by cultured embryos [37,50,54,55]. Besides, pores in bovine embryos zona
616 pellucida are of about 200 nm [56], which matches the size of EVs isolated from the
617 fluids used in embryo culture. Therefore, as EVs are taken up by embryos, their cargo,
618 which includes proteins, mRNA, miRNA, among other molecules [57], can affect
619 embryo functions during in vitro culture, and may contribute, at least in part, to the
620 effects seen in the present study. One curious observation was that some of the effects
621 of EVs appeared to be affected by the type of protein supplementation present in the
622 embryo culture media (BSA or dFCS), and in most cases was observed when dFCS was
623 the protein source (more details in following sections). The reasons for this are unclear,
624 but could be related with serum somehow affecting the process of EVs uptake or of a
625 subpopulation of the vesicles. Studies on effects of culture conditions are mostly
626 focussed on EVs secretion, and quantitative analysis and characterization of factors
627 affecting EVs uptake are not well defined, as also separating EVs subpopulations [58–
628 60]. However, a recent study using HeLa and A431 cell lines, showed that uptake may
629 be increased in presence of serum [61], so differences in uptake efficiency could impact
630 target cell response and this could be a possibility also in embryos. This level of
631 analysis was not the aim of this experiment and the method used (fluorescent lipophilic

632 dye staining) would not be appropriate for such study [62], but this would be an
633 interesting point to consider in future studies.

634 **In vitro embryo development**

635 EVs supplementation during embryo culture in vitro did not improve embryo
636 development, as blastocyst rates were similar in dFCS and dFCS-EV groups.
637 Surprisingly, however, development was reduced when EVs were added to BSA
638 containing medium. When culturing embryos with complete FCS and EVs isolated from
639 BOECs conditioned medium, lack of effect of EVs have also been reported [28]. In
640 contrast, positive effect of EVs on embryo development has been observed by Qiao et
641 al. [39] when using EVs only from UF in medium with BSA from D4 and by Almiñana
642 et al. [37] using EVs only from OF in medium with dFCS. Differences in culture
643 conditions (only OF or only UF EVs vs sequential use of OF and UF-EVs), type of
644 embryo (cloned embryos in [39]), EVs isolation method and amount of EVs
645 supplemented to culture medium, could account for the diverging results between
646 studies. Regarding EVs in medium with BSA, Lopera-Vasquez et al. [36] and Banliat et
647 al. [63] did not report any effect of EVs, contrary to our observations, but they both
648 used different isolation methods. No other studies have directly compared EVs addition
649 in culture media with different protein supplementation, so the reasons for diverging
650 effects of EVs when using BSA or dFCS are unknown, but as mentioned earlier, serum
651 could affect EVs uptake, as seen in cell lines [61], which could lead to different effects
652 on cells.

653 **Embryo quality**

654 **Vitrification**

655 When assessing embryo quality by blastocyst survival rates at 72 hours after
656 vitrification and warming showed that addition of EVs had no effects in medium with
657 BSA, as BSA-EV did not differ from its respective control (73 x 67% for BSA-EV and
658 BSA, respectively). However, the addition of EVs to dFCS group increased survival
659 (87.8 vs 69.2%, respectively), indicating a positive effect of EVs in presence of serum.
660 The supplementation of EVs in embryo culture medium and effects on cryotolerance
661 were reported in only two previous studies. Lopera-Vasquez et al. [28] observed that
662 using EVs isolated from BOECs conditioned-medium, but in medium devoid of any
663 protein source, had higher survival rates compared to complete serum (50 x 20%). This
664 effect, however, could be due to the exclusion of serum, as this has been shown to
665 increase embryo cryotolerance (56 x 26%, Lopera-Vasquez et al. [29]). Also, the use of
666 either BSA or dFCS alone improved cryotolerance [28–30,36], and no additional effects
667 of OF, OF+UF or EVs from BOECs were reported. However, a positive effect of
668 oviduct EVs has been described when they were isolated from the isthmus of the
669 oviduct (80 x 51%), suggesting that EVs may differ depending on the region from
670 which they were isolated [36]. The characterization of EVs from different regions
671 would be interesting to bring new information to better understand their different effects
672 on aspects of embryo development and quality. Nevertheless, in the present study, EVs
673 were isolated from the whole oviduct and used in sequence with EVs from the uterus, so
674 conditions are different, but a positive effect was also observed. Besides, this was the
675 same group showing lower lipids, suggesting this could be related to better
676 cryotolerance as previously reported [15–18].

677 **Total cell numbers**

678 Blastocyst quality was also assessed by other parameters including total cell numbers,
679 mitochondrial activity and lipid content. Our results using EVs from OF and UF in

680 sequential culture corroborate previous studies of a positive effect on cell numbers.
681 Indeed, increased cell numbers in embryos were also reported when using EVs isolated
682 from BOECs-conditioned medium with BSA [28], from UF in medium with BSA from
683 D4 to D8 [39], and also from OF in medium with dFCS [37]. EVs isolated from
684 medium conditioned by cultured embryos also show this same effect [55,64].
685 Such effect would be due to a stimulus to cell proliferation as reported by Hung et al.
686 [65], who observed a proliferative effect of EVs from follicular fluid on bovine
687 granulosa cells in vitro. A similar effect could be caused by EVs from OF and UF on
688 embryo cell division. When analysing the transcriptome of EVs from OF, Almiñana et
689 al. [51] reported the presence of transcripts for genes related to cell cycle regulation,
690 which could potentially be transferred by EVs uptaken by embryos, stimulating cell
691 division, therefore increasing embryo cell numbers. Such possibility seems plausible, as
692 horizontal transfer of mRNAs and proteins between bovine granulosa cells were shown
693 to occur through EVs, and phenotypical changes in cells uptaking EVs, including
694 increased proliferation, have also been reported [66]. It would be interesting to further
695 investigate and confirm the transfer, via EVs from OF and/or UF, of molecules
696 regulating the cell cycle in embryos exposed to such vesicles.

697 **Mitochondrial activity**

698 Regarding mitochondrial activity in blastocysts, only dFCS-EV embryos showed
699 increased activity. These results suggest that EVs are capable of stimulating embryo
700 mitochondrial activity, but this effect can be influenced by the protein source in the
701 culture medium, as for embryos cultured with BSA, the presence of EVs had no effect.
702 Coincidentally, the dFCS-EV group that had increased mitochondrial activity also had the
703 lowest lipid contents, therefore this increased activity may go along with higher lipid
704 consumption for β -oxidation in mitochondria of treated embryos. Prastowo et al. [67]

705 have reported a close relationship between lipid contents and mitochondrial function.
706 Bovine granulosa cells exposed to EVs showed an increased in mitochondrial activity
707 [66], therefore, there was an effect from EVs from OF and/or UF on embryonic
708 mitochondrial activity.

709 **Lipid contents**

710 When analysing lipid contents in blastocysts cultured with EVs in a medium with
711 different protein sources, we observed that only the dFCS-EV group had lower contents,
712 suggesting effects of EVs when embryos are cultured with serum, but not with BSA.
713 Substitution of serum for BSA in embryo culture medium has been shown to decrease
714 lipids [68], and apparently the addition of EVs did not result in an additional decrease.
715 On the other hand, embryos cultured with serum usually show increased lipid contents
716 [20]. In the present study, we have used dFCS, which has been shown to improve
717 embryo quality and cryotolerance [28], as also observed with the use of BSA [30],
718 suggesting a possible reduction in lipids.

719 On the other hand, the supplementation of EVs was capable of causing a significant
720 reduction in embryo lipids compared to dFCS alone, which was not different from BSA
721 groups. The mechanism by which EVs would cause such reduction is presently
722 unknown but is probably related to EVs cargo, as it can affect functions in target cells
723 [66]. Almiñana et al. [51] have detected several transcripts for lipid metabolism
724 enzymes and miRNAs that affect them. Therefore, EVs could affect embryo lipid
725 metabolism through modifications on mRNA and/or protein expression. As described
726 later, we have observed changes in transcript abundance for several genes related to
727 lipid metabolism, reinforcing this possibility.

728 Taken together, the observations for total cell number, mitochondrial activity and lipid
729 content indicate that EVs improve parameters related to embryo quality, and also, that

730 such effect can be influenced by the protein source supplemented to the embryo culture
731 medium. To the best of our knowledge, this is the first study to indicate the effects of
732 EVs on mitochondrial activity and lipid metabolism in bovine embryos.

733 **Expression of lipid-metabolism genes**

734 The presence of EVs affected five of the analysed transcripts (*PPARGC1B*, *ACACA*,
735 *CD36*, *PLIN2* and *PNPLA2*) and the patterns of expression were varied. Most
736 transcripts were decreased (*PARGC1B*, *PNPLA2*, *PLIN2* and *CD36*) and two were
737 increased (*ACACA* and *CD36*). The most common outcome of miRNAs on mRNA
738 levels is a decrease by degradation of the targeted transcript [69], however, increased
739 transcription may also be induced by miRNAs [70,71]. On the other hand, increased
740 transcripts in target cells may be a result of direct transfer of mRNA, and this could be
741 the case for *ACACA* and *CD36*, as their transcripts were identified in OF-EVs [51].
742 However, miRNAs that can target *ACACA* [51] were also identified in this study.
743 mRNAs for *PPARGC1B*, *PNPLA2* and *PLIN2* were also detected in OF-EVs by
744 Almiñana et al. [51], but they were decreased in embryos in this study, as were for
745 *LDLR* and *FASN* that were not affected, so transfer of mRNAs would not explain this
746 outcome. Regulation of target cells functions by EVs is quite a complex topic and yet
747 undergoing expansion of knowledge. Bauersachs et al. [72] have analysed mRNA and
748 miRNAs contents reported as present in OF-EVs and compared with the transcriptome
749 of embryos cultured with such EVs, and concluded they do regulate expression in
750 embryos and that such regulation may be carried out by different mechanisms including
751 increased delivery of mRNAs, translation of delivered mRNAs into proteins that then
752 modulate expression or by miRNAs that downregulate mRNAs or modify expression in
753 other ways. Whether miRNAs and/or mRNAs in EVs used in this study are influencing
754 these transcripts cannot be discriminated, and warrant further studies.

755 Another observation regarding effects of EVs, was that some transcripts were affected
756 differently by EVs depending on the protein source present in culture medium. *PNPLA2*
757 and *PLIN2*, both decreased, but only when EVs were added to medium containing BSA
758 or dFCS, respectively. Also, *CD36* showed an inverse response, where EVs lead to
759 upregulation when in medium with dFCS, and upregulation with BSA. Reasons for this
760 outcome are unknown, but could be partly related with the presence of serum, as some
761 differences in other results in this study appeared to be influenced mostly by serum.
762 BSA does not contain EVs [55], but serum, although depleted of its EVs, still has some
763 left, as the depletion process (ultracentrifugation) does not result in their complete
764 removal [73,74]. Thus, some EVs still present in dFCS in association with those added
765 to the culture medium (from OF and UF in this study), could lead to a different effect
766 than when adding to medium containing BSA, which would have only the added EVs
767 from the fluids. Also, as mentioned before, if serum can somehow affect uptake of EVs,
768 as observed in other cells [61], this would in turn also affect cargo delivery and the
769 function of target cell. More studies are needed to understand the interactions between
770 EVs, protein source and their effects on embryonic gene expression.

771 Taken together, EVs were shown to affect transcripts levels of lipid-related genes,
772 involved in different aspects of lipid metabolism as lipogenesis (*PPARGC1B* and
773 *ACACA*), lipolysis (*PNPLA2*), lipid uptake (*CD36*) and accumulation (*PLIN2*), so EVs
774 from OF and/or UF may influence lipid metabolism of embryos. Also, type of protein
775 source in culture medium may interfere in the effect of these EVs in vitro.

776 **Lipid metabolism proteins**

777 HSL is an essential enzyme in lipolysis and is activated when phosphorylated [75].
778 Confirming its presence at mRNA level, HSL protein was also detected, as was its

779 phosphorylated (active) form (pHSL) in all groups, showing that the enzyme is also
780 functional in bovine embryos. This protein had only been detected previously in bovine
781 oocytes and cumulus cells [76,77]. This is the first confirmation of its protein in
782 embryos, indicating its certain participation in embryonic lipid metabolism, as the
783 activated form was also present. HSL phosphorylation level was lower in dFCS,
784 suggesting this groups would have lower lipolysis rates, and this could be related to the
785 higher amount of lipids found in this group. The presence of EVs in the medium with
786 dFCS had a positive effect on the stimulation of lipolysis and could counteract the effect
787 of serum suggesting an important role in embryonic lipid metabolism. Recently, Zhuan
788 et al. [78] have shown in porcine oocytes that stimulation of HSL activity improves
789 oocyte maturation and embryo development, while its inhibition resulted in increased
790 lipids in oocytes, associated with lower mitochondrial activity. This is in accordance
791 with our observation that lower active HSL corresponded with higher lipid amounts and
792 lower mitochondrial activity in dFCS blastocysts compared to those to which EVs were
793 added to culture with dFCS.

794 Interestingly, transcript levels for HSL did not vary with any treatment, further
795 supporting the idea that transcript levels do not correlate to lipases activities [79], and
796 that detection of the active form of the enzyme can be a better indicator of effects on
797 lipid metabolism. The mechanism by which EVs could affect activity of HSL is
798 unknown, but EVs have been shown to participate in the regulation of cell metabolism
799 by multiple pathways [80].

800 **miRNA in EVs used for IVC**

801 As EVs may carry different types of cargo and among them there are miRNAs, which
802 are small molecules known to modulate target-cell function through effects on the

803 expression of transcripts and proteins [69–71]. Therefore, we also looked at their
804 content in the EVs used in our culture system. From the twenty most abundant miRNAs
805 in EVs from OF and UF, bta-miR-200b was also detected by Almiñana et al. [51] in
806 EVs from bovine OF samples. When comparing miRNA contents in EVs from OF and
807 UF, two of the differentially expressed (bta-miR-151-3p and bta-miR-24-3p), were also
808 reported in EVs from OF in the same study, in agreement with present observations.
809 These two miRNAs are involved in the control of expression of *FASN* and *ACACA* [51],
810 which are genes related with lipid metabolism, and both transcripts were detected in
811 embryos in this study, but only *ACACA* was influenced by the EVs supplementation in
812 the culture medium. EVs increased transcripts for *ACACA* possibly due to one or both
813 of these miRNAs, as these molecules may also induce transcription [70,71]. And
814 although *FASN* transcripts were not affected, it is possible that miRNAs interfered with
815 protein levels. This possibility, however, remains to be addressed in future studies.

816 Some of the miRNA detected in EVs from OF and UF samples, such as bta-miR-181,
817 bta-let-7a, bta-let-7b, bta-miR29a, bta-miR-151 and bta-miR-494 have been related with
818 implantation in mice [81,82], sheep [83] and humans [84]. From the 20 differentially
819 expressed, almost all of them were more abundant in EVs from UF, suggesting that
820 these miRNAs could be involved with the arrival of the embryo to the uterus. The only
821 miRNA that was lower in EVs from UF compared to those from OF (bta-miR-148b)
822 was reported to be related to the suppression of proliferation, migration, and invasion in
823 human tumour cells [85], suggesting that its reduction in the uterus would allow for an
824 increase in these cell activities, necessary for embryo implantation in the uterus. This
825 miRNA was also related with the action of interferon- τ produced by embryonic
826 trophoblastic cells, which lowers the expression of this miRNA to reduce the
827 inflammatory response in bovine endometrial epithelial cells [86]. This observation

828 suggests that the reduction of bta-miR-148b in the uterus compared to the oviduct,
829 could be related with favouring the implantation process, but more studies are necessary
830 to address this assumption. As nearly all differentially expressed miRNAs were
831 upregulated in the uterine EVs, this is probably a reflection of the highly complex
832 function of the uterus in regulating embryo development and the process of
833 implantation and placental development. Most studies on uterine EVs and miRNAs in
834 bovine have addressed the peri-implantation period (D16-22, [38,87–90]) and have
835 shown the importance of embryo-maternal communication through EVs during this
836 period [91]. However, the cross-talk between the embryo and uterine epithelium is quite
837 intense also at early stages of development (D5-8 as in our model; [92]), and EVs and
838 miRNAs may probably participate in this communication. Interestingly, one of the
839 upregulated miRNAs in UF-EVs was bta-miR-155, which was shown to be more
840 expressed in in vivo produced embryos between D7-9 of development compared to
841 those in vitro [93]. This miRNA could be indicative of better quality of embryos and
842 maybe transferred or induced by uterine EVs.

843 As there are no studies comparing EVs from OF and UF and especially regarding the
844 miRNAs in EVs from bovine UF, the roles of these miRNAs for early embryo
845 development remain to be investigated. Even though miRNAs in EVs can regulate
846 functions in target-cell [94], it is also possible, that at least part of effects reported in
847 this study, could be due to the other constituents of their cargo. Bauersachs et al. [72]
848 reported that both mRNA and miRNA in OF EVs regulate the transcriptome of embryos
849 cultured with them, and by varied mechanisms. Lipidome in EVs is less studied [95],
850 but recently Banliat et al. [63] compared the lipidome in OF EVs and of embryos
851 exposed to these EVs and observed changes in embryonic lipids profile. Therefore, it

852 must be considered that other cargoes (mRNA, proteins, bioactive lipids, among others),
853 may also be involved in effects caused by EVs during IVC.

854 **Conclusions**

855 Although EVs do not affect embryo yield, they improve quality parameters including
856 cell number, and when in medium with dFCS, they reduced lipid contents and increased
857 mitochondrial activity and post-vitrification survival; such observations are possibly
858 given, at least in part, by effects on expression of lipid metabolism related genes,
859 modulating their expression by mRNAs, miRNAs and/or proteins contained in these
860 EVs, besides an increase in the active form of HSL, suggesting activated lipolysis.
861 Further studies are needed to understand which cargo may be affecting which cellular
862 functions and how they may be leading to the observed results, something quite
863 challenging as it is still difficult to isolate different types of EVs, which carry different
864 components within.

865 **Abbreviations**

866 IVC: In vitro culture, IVP: In vitro production, EVs: extracellular vesicles, OF:
867 Oviductal fluid, UF: uterine fluid, dFCS: EVs-depleted fetal calf serum, FCS: Fetal calf
868 serum, BSA: bovine serum albumin, miRNAs: microRNAs, NTA: nanoparticle tracking
869 analysis, TEM: transmission electron microscopy, *LDLR*: low density lipoprotein
870 receptor, *ACACA*: acetyl-CoA carboxylase alpha, previous name ACC, *FASN*: fatty
871 acid synthase, alias FAS, *PLIN2*: perilipin 2, *PNPLA2*: patatin like phospholipase
872 domain containing 2, alias ATGL adipose triglyceride lipase, *PPARGC1B*: PPARG
873 coactivator 1 beta, *FAPBP3*: fatty acid binding protein 3, LIPE: lipase E, hormone
874 sensitive type, alias HSL hormone sensitive lipase.

875 **Supplementary Information**

876 **Additional file 1: Table S1.** Details of primers used for reverse transcription–quantitative
877 polymerase chain reaction.

878 **Additional file 2: Table S2.** Top 20 miRNA in EVs from OF and UF

879 **Declarations**

880 **Ethics approval and consent to participate**

881 Not applicable.

882 **Consent for publication**

883 Not applicable.

884 **Availability of data and materials**

885 The raw data supporting the conclusion of this article will be made available by the
886 authors, without undue reservation, to any qualified researcher. In addition, all
887 generated or analysed data derived from this study are included in this published article
888 and its Supplementary data files

889 **Competing interests**

890 The authors declare that the research was conducted in the absence of any commercial
891 or financial relationships that could be construed as a potential conflict of interest.

892 **Funding**

893 This work was supported by the Spanish Ministry of Science and Innovation (PID2019-
894 111641RB-I00 to DR, and RTI2018-093548-B-I00 to AGA); São Paulo Research
895 Foundation, Brazil (FAPESP; #2017/20339-3 and CNPq-Brazil 304276/2018-9 to
896 CLVL; #2019/04981-2 to RM; 2014/22887-0 and 2015/21829-9 to JCDS);
897 Minciencias-Colombia Postdoctoral Fellowship (848-2019) to KC-B; Secretaria de

898 Educación Superior, Ciencia y Tecnología e Innovación (SENESCYT-Ecuador) to
899 YNC.

900 **Authors' contributions**

901 CLVL and DR supervised the project and designed the experiments. CLVL, KC-B,
902 YNC, MH, AY, MGMB, PBB, EG, RM and JCS performed the experiments. CLVL,
903 KC-B, YNC, MH, EG, RM, JCS, AGA and DR analyzed the experiments and provided
904 technical support and discussions. CLVL, KC-B, YNC, MH and DR wrote the
905 manuscript. All the authors reviewed the manuscript.

906 **Acknowledgments**

907 Special thanks are extended to the: slaughterhouses (Transformación Ganadera de
908 Leganés SA; Matadero de Madrid Norte, San Agustín de Guadalix; and Carnica
909 Colmenar SC, in Madrid, Spain) for providing access to the biological material
910 (ovaries) used in the present study and to the Spanish Association of Breeders of
911 Selected Cattle of the Asturian Valley Breed (ASEAVA) for providing the semen
912 used in the present study. We thank from the Department of Animal Biotechnology,
913 CSIC-INIA, Dr. Covadonga Alonso for the use the confocal microscope and Dr. Rafael
914 Blasco Lozano and Dr. María del Mar Lorenzo Gilsanz for the use of the
915 ultracentrifuge; Dr. Maria Jesus Cocero and Mrs. Pilar Marigorta from the Department
916 of Animal Reproduction, CSIC-INIA for the use of the epifluorescence microscope.

917

918 **Authors' details**

919 ¹Department of Animal Reproduction, National Center Institute for Agriculture and
920 Food Research and Technology (CSIC-INIA), 28040, Madrid, Spain. ²Department of
921 Veterinary Medicine, Faculdade de Zootecnia e Engenharia de Alimentos, Universidade
922 de São Paulo (FZEA-USP), Pirassununga, Brazil. ³Facultad de Ciencias Agrarias y

923 Ambientales, Programa de Medicina Veterinaria, Fundación Universitaria Juan de
924 Castellanos, Tunja, Colombia. ⁴Laboratorio de Biotecnología de la Reproducción
925 Animal, Facultad de Ciencias Agropecuarias, Universidad de Cuenca (UC), EC010205,
926 Cuenca, Ecuador. ⁵Department of Anatomy and Embryology, Veterinary Faculty-
927 Universidad Complutense de Madrid (UCM), Madrid, Spain

928

929 References

- 930 1. Ferré, L.B.; Kjelland, M.E.; Strøbech, L.B.; Hyttel, P.; Mermillod, P.; Ross, P.J. Review: Recent
931 Advances in Bovine in Vitro Embryo Production: Reproductive Biotechnology History and
932 Methods. *Animal* 2020, 14, 991–1004, doi:10.1017/S1751731119002775.
- 933 2. Rizos, D.; Fair, T.; Papadopoulos, S.; Boland, M.P.; Lonergan, P. Developmental, Qualitative, and
934 Ultrastructural Differences between Ovine and Bovine Embryos Produced in Vivo or in Vitro. *Mol.*
935 *Reprod. Dev.* 2002, 62, 320–327, doi:10.1002/mrd.10138.
- 936 3. Rizos, D.; Lonergan, P.; Boland, M.P.; Arroyo-García, R.; Pintado, B.; Fuente, J. de la; Gutiérrez-
937 Adán, A. Analysis of Differential Messenger RNA Expression Between Bovine Blastocysts
938 Produced in Different Culture Systems: Implications for Blastocyst Quality1. *Biol. Reprod.* 2002,
939 66, 589–595, doi:10.1095/biolreprod66.3.589.
- 940 4. Rizos, D.; Ward, F.; Duffy, P.; Boland, M.P.; Lonergan, P. Consequences of Bovine Oocyte
941 Maturation, Fertilization or Early Embryo Development in Vitro versus in Vivo: Implications for
942 Blastocyst Yield and Blastocyst Quality. *Mol. Reprod. Dev.* 2002, 61, 234–248,
943 doi:10.1002/mrd.1153.
- 944 5. Rizos, D.; Clemente, M.; Bermejo-Alvarez, P.; Fuente, J.D.L.; Lonergan, P.; Gutiérrez-Adán, A.
945 Consequences of In Vitro Culture Conditions on Embryo Development and Quality. *Reprod.*
946 *Domest. Anim.* 2008, 43, 44–50, doi:10.1111/j.1439-0531.2008.01230.x.
- 947 6. Niemann, H.; Wrenzycki, C. Alterations of Expression of Developmentally Important Genes in
948 Preimplantation Bovine Embryos by in Vitro Culture Conditions: Implications for Subsequent
949 Development. *Theriogenology* 2000, 53, 21–34, doi:10.1016/S0093-691X(99)00237-X.
- 950 7. Khurana, N.K.; Niemann, H. Energy Metabolism in Preimplantation Bovine Embryos Derived in
951 Vitro or in Vivo. *Biol. Reprod.* 2000, 62, 847–856, doi:10.1095/biolreprod62.4.847.
- 952 8. de Souza, D.K.; Salles, L.P.; Rosa e Silva, A.A.M. Aspects of Energetic Substrate Metabolism of in
953 Vitro and in Vivo Bovine Embryos. *Braz. J. Med. Biol. Res.* 2015, 48, 191–197, doi:10.1590/1414-
954 431X20143744.
- 955 9. Holm, P.; Callesen, H. In vivo versus in vitro produced bovine ova: similarities and differences
956 relevant for practical application. *Reprod. Nutr. Dev.* 1998, 38, 579–594,
957 doi:10.1051/rnd:19980601.
- 958 10. Ushijima, H.; Akiyama, K.; Tajima, T. Transition of Cell Numbers in Bovine Preimplantation
959 Embryos: In Vivo Collected and In Vitro Produced Embryos. *J. Reprod. Dev.* 2008, 54, 239–243,
960 doi:10.1262/jrd.19128.
- 961 11. Pontes, J.H.F.; Nonato-Junior, I.; Sanches, B.V.; Ereno-Junior, J.C.; Uvo, S.; Barreiros, T.R.R.;
962 Oliveira, J.A.; Hasler, J.F.; Seneda, M.M. Comparison of Embryo Yield and Pregnancy Rate
963 between in Vivo and in Vitro Methods in the Same Nelore (*Bos Indicus*) Donor Cows.
964 *Theriogenology* 2009, 71, 690–697, doi:10.1016/j.theriogenology.2008.09.031.
- 965 12. Ealy, A.D.; Wooldridge, L.K.; McCoski, S.R. BOARD INVITED REVIEW: Post-Transfer
966 Consequences of in Vitro-Produced Embryos in Cattle. *J. Anim. Sci.* 2019, 97, 2555–2568,
967 doi:10.1093/jas/skz116.
- 968 13. Havlicek, V.; Kuzmany, A.; Cseh, S.; Brem, G.; Besenfelder, U. The Effect of Long-Term In Vivo
969 Culture in Bovine Oviduct and Uterus on the Development and Cryo-Tolerance of In Vitro
970 Produced Bovine Embryos. *Reprod. Domest. Anim.* 2010, 45, 832–837, doi:10.1111/j.1439-
971 0531.2009.01364.x.

- 972 14. Barceló-Fimbres, M.; Seidel Jr., G. e. Effects of Fetal Calf Serum, Phenazine Ethosulfate and
973 Either Glucose or Fructose during in Vitro Culture of Bovine Embryos on Embryonic Development
974 after Cryopreservation. *Mol. Reprod. Dev.* 2007, 74, 1395–1405, doi:10.1002/mrd.20699.
- 975 15. Diez, C.; Heyman, Y.; Le Bourhis, D.; Guyader-Joly, C.; Degrouard, J.; Renard, J.P. Delipidating
976 in Vitro-Produced Bovine Zygotes: Effect on Further Development and Consequences for
977 Freezability. *Theriogenology* 2001, 55, 923–936, doi:10.1016/S0093-691X(01)00454-X.
- 978 16. Barceló-Fimbres, M.; Seidel, G.E. Cross-Validation of Techniques for Measuring Lipid Content of
979 Bovine Oocytes and Blastocysts. *Theriogenology* 2011, 75, 434–444,
980 doi:10.1016/j.theriogenology.2010.09.007.
- 981 17. Paschoal, D.M.; Sudano, M.J.; Schwarz, K.R.L.; Maziero, R.R.D.; Guastali, M.D.; Crocomo, L.F.;
982 Magalhães, L.C.O.; Martins, A.; Leal, C.L.V.; Landim-Alvarenga, F. da C. Cell Apoptosis and
983 Lipid Content of in Vitro-Produced, Vitrified Bovine Embryos Treated with Forskolin.
984 *Theriogenology* 2017, 87, 108–114, doi:10.1016/j.theriogenology.2016.08.011.
- 985 18. Cañón-Beltrán, K.; Giraldo-Giraldo, J.; Cajas, Y.N.; Beltrán-Breña, P.; Hidalgo, C.O.; Vásquez,
986 N.; Leal, C.L.V.; Gutiérrez-Adán, A.; González, E.M.; Rizos, D. Inhibiting Diacylglycerol
987 Acyltransferase-1 Reduces Lipid Biosynthesis in Bovine Blastocysts Produced in Vitro.
988 *Theriogenology* 2020, 158, 267–276, doi:10.1016/j.theriogenology.2020.09.014.
- 989 19. Abe, H.; Yamashita, S.; Satoh, T.; Hoshi, H. Accumulation of Cytoplasmic Lipid Droplets in
990 Bovine Embryos and Cryotolerance of Embryos Developed in Different Culture Systems Using
991 Serum-Free or Serum-Containing Media. *Mol. Reprod. Dev.* 2002, 61, 57–66,
992 doi:10.1002/mrd.1131.
- 993 20. Rizos, D.; Gutiérrez-Adán, A.; Pérez-Garnelo, S.; De La Fuente, J.; Boland, M.P.; Lonergan, P.
994 Bovine Embryo Culture in the Presence or Absence of Serum: Implications for Blastocyst
995 Development, Cryotolerance, and Messenger RNA Expression. *Biol. Reprod.* 2003, 68, 236–243,
996 doi:10.1095/biolreprod.102.007799.
- 997 21. Leroy, J.; Genicot, G.; Donnay, I.; Van Soom, A. Evaluation of the Lipid Content in Bovine
998 Oocytes and Embryos with Nile Red: A Practical Approach. *Reprod. Domest. Anim.* 2005, 40, 76–
999 78, doi:10.1111/j.1439-0531.2004.00556.x.
- 1000 22. Collado, M. del; Saraiva, N.Z.; Lopes, F.L.; Gaspar, R.C.; Padilha, L.C.; Costa, R.R.; Rossi, G.F.;
1001 Vantini, R.; Garcia, J.M. Influence of Bovine Serum Albumin and Fetal Bovine Serum
1002 Supplementation during in Vitro Maturation on Lipid and Mitochondrial Behaviour in Oocytes and
1003 Lipid Accumulation in Bovine Embryos. *Reprod. Fertil. Dev.* 2016, 28, 1721–1732,
1004 doi:10.1071/RD15067.
- 1005 23. Heras, S.; De Coninck, D.I.M.; Van Poucke, M.; Goossens, K.; Bogado Pascottini, O.; Van
1006 Nieuwerburgh, F.; Deforce, D.; De Sutter, P.; Leroy, J.L.M.R.; Gutierrez-Adan, A.; et al.
1007 Suboptimal Culture Conditions Induce More Deviations in Gene Expression in Male than Female
1008 Bovine Blastocysts. *BMC Genomics* 2016, 17, 72, doi:10.1186/s12864-016-2393-z.
- 1009 24. Hackett, A.J.; Durnford, R.; Mapletoft, R.J.; Marcus, G.J. Location and Status of Embryos in the
1010 Genital Tract of Superovulated Cows 4 to 6 Days after Insemination. *Theriogenology* 1993, 40,
1011 1147–1153, doi:10.1016/0093-691X(93)90285-D.
- 1012 25. Hugentobler, S.A.; Diskin, M.G.; Leese, H.J.; Humpherson, P.G.; Watson, T.; Sreenan, J.M.;
1013 Morris, D.G. Amino Acids in Oviduct and Uterine Fluid and Blood Plasma during the Estrous
1014 Cycle in the Bovine. *Mol. Reprod. Dev.* 2007, 74, 445–454, doi:10.1002/mrd.20607.
- 1015 26. Rodríguez-Alonso, B.; Sánchez, J.M.; González, E.; Lonergan, P.; Rizos, D. Challenges in
1016 Studying Preimplantation Embryo-Maternal Interaction in Cattle. *Theriogenology* 2020, 150, 139–
1017 149, doi:10.1016/j.theriogenology.2020.01.019.
- 1018 27. Saint-Dizier, M.; Schoen, J.; Chen, S.; Banliat, C.; Mermillod, P. Composing the Early Embryonic
1019 Microenvironment: Physiology and Regulation of Oviductal Secretions. *Int. J. Mol. Sci.* 2020, 21,
1020 223, doi:10.3390/ijms21010223.
- 1021 28. Lopera-Vásquez, R.; Hamdi, M.; Fernandez-Fuertes, B.; Mailló, V.; Beltrán-Breña, P.; Calle, A.;
1022 Redruello, A.; López-Martín, S.; Gutierrez-Adán, A.; Yañez-Mó, M.; et al. Extracellular Vesicles
1023 from BOEC in In Vitro Embryo Development and Quality. *PLoS One* 2016, 11, e0148083,
1024 doi:10.1371/journal.pone.0148083.
- 1025 29. Lopera-Vasquez, R.; Hamdi, M.; Mailló, V.; Lloreda, V.; Coy, P.; Gutierrez-Adan, A.; Bermejo-
1026 Alvarez, P.; Rizos, D. Effect of Bovine Oviductal Fluid on Development and Quality of Bovine
1027 Embryos Produced in Vitro. *Reprod. Fertil. Dev.* 2017, 29, 621–629, doi:10.1071/RD15238.
- 1028 30. Hamdi, M.; Lopera-Vasquez, R.; Mailló, V.; Sanchez-Calabuig, M.J.; Núñez, C.; Gutierrez-Adan,
1029 A.; Rizos, D. Bovine Oviductal and Uterine Fluid Support in Vitro Embryo Development. *Reprod.*
1030 *Fertil. Dev.* 2018, 30, 935–945, doi:10.1071/RD17286.

- 1031 31. Ellwanger, J.H.; Veit, T.D.; Chies, J.A.B. Exosomes in HIV Infection: A Review and Critical
1032 Look. *Infect. Genet. Evol.* 2017, 53, 146–154, doi:10.1016/j.meegid.2017.05.021.
- 1033 32. Huang-Doran, I.; Zhang, C.-Y.; Vidal-Puig, A. Extracellular Vesicles: Novel Mediators of Cell
1034 Communication In Metabolic Disease. *Trends Endocrinol. Metab.* 2017, 28, 3–18,
1035 doi:10.1016/j.tem.2016.10.003.
- 1036 33. Théry, C.; Witwer, K.W.; Aikawa, E.; Alcaraz, M.J.; Anderson, J.D.; Andriantsitohaina, R.;
1037 Antoniou, A.; Arab, T.; Archer, F.; Atkin-Smith, G.K.; et al. Minimal Information for Studies of
1038 Extracellular Vesicles 2018 (MISEV2018): A Position Statement of the International Society for
1039 Extracellular Vesicles and Update of the MISEV2014 Guidelines. *J. Extracell. Vesicles* 2018, 7,
1040 1535750, doi:10.1080/20013078.2018.1535750.
- 1041 34. O'Neil, E.V.; Burns, G.W.; Spencer, T.E. Extracellular Vesicles: Novel Regulators of Conceptus-
1042 Uterine Interactions? *Theriogenology* 2020, 150, 106–112,
1043 doi:10.1016/j.theriogenology.2020.01.083.
- 1044 35. Bridi, A.; Perecin, F.; Silveira, J.C. da Extracellular Vesicles Mediated Early Embryo-Maternal
1045 Interactions. *Int. J. Mol. Sci.* 2020, 21, doi:10.3390/ijms21031163.
- 1046 36. Lopera-Vasquez, R.; Hamdi, M.; Maillou, V.; Gutierrez-Adan, A.; Bermejo-Alvarez, P.; Ramirez,
1047 M.Á.; Yáñez-Mó, M.; Rizos, D. Effect of Bovine Oviductal Extracellular Vesicles on Embryo
1048 Development and Quality in Vitro. *Reproduction* 2017, 153, 461–470, doi:10.1530/REP-16-0384.
- 1049 37. Almiñana, C.; Corbin, E.; Tsikis, G.; Alcântara-Neto, A.S.; Labas, V.; Reynaud, K.; Galio, L.;
1050 Uzbekov, R.; Garanina, A.S.; Druart, X.; et al. Oviduct Extracellular Vesicles Protein Content and
1051 Their Role during Oviduct–Embryo Cross-Talk. *Reproduction* 2017, 154, 253–268,
1052 doi:10.1530/REP-17-0054.
- 1053 38. Kusama, K.; Nakamura, K.; Bai, R.; Nagaoka, K.; Sakurai, T.; Imakawa, K. Intrauterine Exosomes
1054 Are Required for Bovine Conceptus Implantation. *Biochem. Biophys. Res. Commun.* 2018, 495,
1055 1370–1375, doi:10.1016/j.bbrc.2017.11.176.
- 1056 39. Qiao, F.; Ge, H.; Ma, X.; Zhang, Y.; Zuo, Z.; Wang, M.; Zhang, Y.; Wang, Y. Bovine Uterus-
1057 Derived Exosomes Improve Developmental Competence of Somatic Cell Nuclear Transfer
1058 Embryos. *Theriogenology* 2018, 114, 199–205, doi:10.1016/j.theriogenology.2018.03.027.
- 1059 40. Bartel, D.P. MicroRNAs: Target Recognition and Regulatory Functions. *Cell* 2009, 136, 215–233,
1060 doi:10.1016/j.cell.2009.01.002.
- 1061 41. Cañón-Beltrán, K.; Hamdi, M.; Mazzarella, R.; Cajas, Y.N.; Leal, C.L.V.; Gutiérrez-Adán, A.;
1062 González, E.M.; da Silveira, J.C.; Rizos, D. Isolation, Characterization, and MicroRNA Analysis of
1063 Extracellular Vesicles from Bovine Oviduct and Uterine Fluids. In *Next Generation Culture
1064 Platforms for Reliable In Vitro Models*; Brevini, T.A.L., Fazeli, A., Turksen, K., Eds.; *Methods in
1065 Molecular Biology*; Springer US: New York, NY, 2021; Vol. 2273, pp. 219–238 ISBN 978-1-07-
1066 161245-3.
- 1067 42. Ireland, J.J.; Murphee, R.L.; Coulson, P.B. Accuracy of Predicting Stages of Bovine Estrous Cycle
1068 by Gross Appearance of the Corpus Luteum. *J. Dairy Sci.* 1980, 63, 155–160,
1069 doi:10.3168/jds.S0022-0302(80)82901-8.
- 1070 43. Lässer, C.; Eldh, M.; Lötvall, J. Isolation and Characterization of RNA-Containing Exosomes. *J.*
1071 *Vis. Exp. JoVE* 2012, 3037, doi:10.3791/3037.
- 1072 44. da Silveira, J.C.; de Ávila, A.C.F.C.M.; Garrett, H.L.; Bruemmer, J.E.; Winger, Q.A.; Bouma, G.J.
1073 Cell-Secreted Vesicles Containing MicroRNAs as Regulators of Gamete Maturation. *J. Endocrinol.*
1074 2018, 236, R15–R27, doi:10.1530/JOE-17-0200.
- 1075 45. Holm, P.; Booth, P.J.; Schmidt, M.H.; Greve, T.; Callesen, H. High Bovine Blastocyst
1076 Development in a Static in Vitro Production System Using Sofaa Medium Supplemented with
1077 Sodium Citrate and Myo-Inositol with or without Serum-Proteins. *Theriogenology* 1999, 52, 683–
1078 700, doi:10.1016/S0093-691X(99)00162-4.
- 1079 46. Cajas, Y.N.; Cañón-Beltrán, K.; Ladrón de Guevara, M.; Millán de la Blanca, M.G.; Ramos-Ibeas,
1080 P.; Gutiérrez-Adán, A.; Rizos, D.; González, E.M. Antioxidant Nobiletin Enhances Oocyte
1081 Maturation and Subsequent Embryo Development and Quality. *Int. J. Mol. Sci.* 2020, 21, 5340,
1082 doi:10.3390/ijms21155340.
- 1083 47. Bermejo-Álvarez, P.; Rizos, D.; Rath, D.; Lonergan, P.; Gutierrez-Adan, A. Epigenetic Differences
1084 between Male and Female Bovine Blastocysts Produced in Vitro. *Physiol. Genomics* 2008, 32,
1085 264–272, doi:10.1152/physiolgenomics.00234.2007.
- 1086 48. Bermejo-Alvarez, P.; Rizos, D.; Rath, D.; Lonergan, P.; Gutierrez-Adan, A. Sex Determines the
1087 Expression Level of One Third of the Actively Expressed Genes in Bovine Blastocysts. *Proc. Natl.*
1088 *Acad. Sci.* 2010, 107, 3394–3399, doi:10.1073/pnas.0913843107.
- 1089 49. Schmittgen, T.D.; Livak, K.J. Analyzing Real-Time PCR Data by the Comparative C T Method.
1090 *Nat. Protoc.* 2008, 3, 1101–1108, doi:10.1038/nprot.2008.73.

- 1091 50. Burns, G.W.; Brooks, K.E.; Spencer, T.E. Extracellular Vesicles Originate from the Conceptus and
1092 Uterus During Early Pregnancy in Sheep. *Biol. Reprod.* 2016, 94, 56,
1093 doi:10.1095/biolreprod.115.134973.
- 1094 51. Almiñana, C.; Tsikis, G.; Labas, V.; Uzbekov, R.; da Silveira, J.C.; Bauersachs, S.; Mermillod, P.
1095 Deciphering the Oviductal Extracellular Vesicles Content across the Estrous Cycle: Implications
1096 for the Gametes-Oviduct Interactions and the Environment of the Potential Embryo. *BMC*
1097 *Genomics* 2018, 19, 622, doi:10.1186/s12864-018-4982-5.
- 1098 52. Tang, Y.-T.; Huang, Y.-Y.; Zheng, L.; Qin, S.-H.; Xu, X.-P.; An, T.-X.; Xu, Y.; Wu, Y.-S.; Hu, X.-
1099 M.; Ping, B.-H.; et al. Comparison of Isolation Methods of Exosomes and Exosomal RNA from
1100 Cell Culture Medium and Serum. *Int. J. Mol. Med.* 2017, 40, 834–844,
1101 doi:10.3892/ijmm.2017.3080.
- 1102 53. Hamdi, M.; Cañon-Beltrán, K.; Mazzarella, R.; Cajas, Y.N.; Leal, C.L.V.; Gutierrez-Adan, A.;
1103 González, E.M.; Da Silveira, J.C.; Rizos, D. Characterization and Profiling Analysis of Bovine
1104 Oviduct and Uterine Extracellular Vesicles and Their MiRNA Cargo through the Estrous Cycle.
1105 *FASEB J.* 2021, 35, e22000, doi:10.1096/fj.202101023R.
- 1106 54. Da Silveira, J.C. da; Andrade, G.M.; Collado, M. del; Sampaio, R.V.; Sangalli, J.R.; Silva, L.A.;
1107 Pinaffi, F.V.L.; Jardim, I.B.; Cesar, M.C.; Nogueira, M.F.G.; et al. Supplementation with small-
1108 extracellular vesicles from ovarian follicular fluid during in vitro production modulates bovine
1109 embryo development. *PLOS ONE* 2017, 12, e0179451, doi:10.1371/journal.pone.0179451.
- 1110 55. Pavani, K.C.; Hendrix, A.; Van Den Broeck, W.; Couck, L.; Szymanska, K.; Lin, X.; De Koster, J.;
1111 Van Soom, A.; Leemans, B. Isolation and Characterization of Functionally Active Extracellular
1112 Vesicles from Culture Medium Conditioned by Bovine Embryos In Vitro. *Int. J. Mol. Sci.* 2019,
1113 20, 38, doi:10.3390/ijms20010038.
- 1114 56. Vanroose, G.; Nauwynck, H.; Soom, A.V.; Ysebaert, M.-T.; Charlier, G.; Oostveldt, P.V.; de Kruif,
1115 A. Structural Aspects of the Zona Pellucida of In Vitro-Produced Bovine Embryos: A Scanning
1116 Electron and Confocal Laser Scanning Microscopic Study1. *Biol. Reprod.* 2000, 62, 463–469,
1117 doi:10.1095/biolreprod62.2.463.
- 1118 57. Mir, B.; Goettsch, C. Extracellular Vesicles as Delivery Vehicles of Specific Cellular Cargo. *Cells*
1119 2020, 9, 1601, doi:10.3390/cells9071601.
- 1120 58. Stranford, D.M.; Hung, M.E.; Gargus, E.S.; Shah, R.N.; Leonard, J.N. A Systematic Evaluation of
1121 Factors Affecting Extracellular Vesicle Uptake by Breast Cancer Cells. *Tissue Eng. Part A* 2017,
1122 23, 1274–1282, doi:10.1089/ten.tea.2017.0158.
- 1123 59. Toribio, V.; Morales, S.; López-Martín, S.; Cardeñes, B.; Cabañas, C.; Yáñez-Mó, M.
1124 Development of a Quantitative Method to Measure EV Uptake. *Sci. Rep.* 2019, 9, 10522,
1125 doi:10.1038/s41598-019-47023-9.
- 1126 60. Carpintero-Fernández, P.; Fafián-Labora, J.; O’Loghlen, A. Technical Advances to Study
1127 Extracellular Vesicles. *Front. Mol. Biosci.* 2017, 4.
- 1128 61. Nakase, I.; Ueno, N.; Matsuzawa, M.; Noguchi, K.; Hirano, M.; Omura, M.; Takenaka, T.;
1129 Sugiyama, A.; Bailey Kobayashi, N.; Hashimoto, T.; et al. Environmental PH Stress Influences
1130 Cellular Secretion and Uptake of Extracellular Vesicles. *FEBS Open Bio* 2021, 11, 753–767,
1131 doi:10.1002/2211-5463.13107.
- 1132 62. Takov, K.; Yellon, D.M.; Davidson, S.M. Confounding Factors in Vesicle Uptake Studies Using
1133 Fluorescent Lipophilic Membrane Dyes. *J. Extracell. Vesicles* 2017, 6, 1388731,
1134 doi:10.1080/20013078.2017.1388731.
- 1135 63. Banliat, C.; Le Bourhis, D.; Bernardi, O.; Tomas, D.; Labas, V.; Salvetti, P.; Guyonnet, B.;
1136 Mermillod, P.; Saint-Dizier, M. Oviduct Fluid Extracellular Vesicles Change the Phospholipid
1137 Composition of Bovine Embryos Developed In Vitro. *Int. J. Mol. Sci.* 2020, 21, 5326,
1138 doi:10.3390/ijms21155326.
- 1139 64. Qu, P.; Qing, S.; Liu, R.; Qin, H.; Wang, W.; Qiao, F.; Ge, H.; Liu, J.; Zhang, Y.; Cui, W.; et al.
1140 Effects of Embryo-Derived Exosomes on the Development of Bovine Cloned Embryos. *PloS One*
1141 2017, 12, e0174535, doi:10.1371/journal.pone.0174535.
- 1142 65. Hung, W.-T.; Navakanitworakul, R.; Khan, T.; Zhang, P.; Davis, J.S.; McGinnis, L.K.;
1143 Christenson, L.K. Stage-Specific Follicular Extracellular Vesicle Uptake and Regulation of Bovine
1144 Granulosa Cell Proliferation†. *Biol. Reprod.* 2017, 97, 644–655, doi:10.1093/biolre/iox106.
- 1145 66. Saeed-Zidane, M.; Linden, L.; Salilew-Wondim, D.; Held, E.; Neuhoff, C.; Tholen, E.; Hoelker,
1146 M.; Schellander, K.; Tesfaye, D. Cellular and exosome mediated molecular defense mechanism in
1147 bovine granulosa cells exposed to oxidative stress. *PLOS ONE* 2017, 12, e0187569,
1148 doi:10.1371/journal.pone.0187569.
- 1149 67. Prastowo, S.; Amin, A.; Rings, F.; Held, E.; Wondim, D.S.; Gad, A.; Neuhoff, C.; Tholen, E.;
1150 Looft, C.; Schellander, K.; et al. Fateful Triad of Reactive Oxygen Species, Mitochondrial

- 1151 Dysfunction and Lipid Accumulation Is Associated with Expression Outline of the AMP-Activated
 1152 Protein Kinase Pathway in Bovine Blastocysts. *Reprod. Fertil. Dev.* 2017, 29, 890–905,
 1153 doi:10.1071/RD15319.
- 1154 68. Abe, H.; Matsuzaki, S.; Hoshi, H. Ultrastructural Differences in Bovine Morulae Classified as High
 1155 and Low Qualities by Morphological Evaluation. *Theriogenology* 2002, 57, 1273–1283,
 1156 doi:10.1016/S0093-691X(02)00634-9.
- 1157 69. Guo, H.; Ingolia, N.T.; Weissman, J.S.; Bartel, D.P. Mammalian MicroRNAs Predominantly Act to
 1158 Decrease Target mRNA Levels. *Nature* 2010, 466, 835–840, doi:10.1038/nature09267.
- 1159 70. Catalanotto, C.; Cogoni, C.; Zardo, G. MicroRNA in Control of Gene Expression: An Overview of
 1160 Nuclear Functions. *Int. J. Mol. Sci.* 2016, 17, 1712, doi:10.3390/ijms17101712.
- 1161 71. Xiao, M.; Li, J.; Li, W.; Wang, Y.; Wu, F.; Xi, Y.; Zhang, L.; Ding, C.; Luo, H.; Li, Y.; et al.
 1162 MicroRNAs Activate Gene Transcription Epigenetically as an Enhancer Trigger. *RNA Biol.* 2016,
 1163 14, 1326–1334, doi:10.1080/15476286.2015.1112487.
- 1164 72. Bauersachs, S.; Mermillod, P.; Almiñana, C. The Oviductal Extracellular Vesicles' RNA Cargo
 1165 Regulates the Bovine Embryonic Transcriptome. *Int. J. Mol. Sci.* 2020, 21,
 1166 doi:10.3390/ijms21041303.
- 1167 73. Kornilov, R.; Puhka, M.; Mannerström, B.; Hiidenmaa, H.; Peltoniemi, H.; Siljander, P.; Seppänen-
 1168 Kaijansinkko, R.; Kaur, S. Efficient Ultrafiltration-Based Protocol to Deplete Extracellular Vesicles
 1169 from Fetal Bovine Serum. *J. Extracell. Vesicles* 2018, 7, 1422674,
 1170 doi:10.1080/20013078.2017.1422674.
- 1171 74. Lehrich, B.M.; Liang, Y.; Fiandaca, M.S. Foetal Bovine Serum Influence on in Vitro Extracellular
 1172 Vesicle Analyses. *J. Extracell. Vesicles* 2021, 10, e12061, doi:10.1002/jev2.12061.
- 1173 75. Proença, A.R.G.; Sertié, R. a. L.; Oliveira, A.C.; Campaãa, A.B.; Caminhotto, R.O.; Chimin, P.;
 1174 Lima, F.B. New Concepts in White Adipose Tissue Physiology. *Braz. J. Med. Biol. Res.* 2014, 47,
 1175 192–205, doi:10.1590/1414-431X20132911.
- 1176 76. Auclair, S.; Uzbekov, R.; Elis, S.; Sanchez, L.; Kireev, I.; Lardic, L.; Dalbies-Tran, R.; Uzbekova,
 1177 S. Absence of Cumulus Cells during in Vitro Maturation Affects Lipid Metabolism in Bovine
 1178 Oocytes. *Am. J. Physiol.-Endocrinol. Metab.* 2013, 304, E599–E613,
 1179 doi:10.1152/ajpendo.00469.2012.
- 1180 77. Schwarz, K.R.L.; Castro, F.C. de; Schefer, L.; Botigelli, R.C.; Paschoal, D.M.; Fernandes, H.; Leal,
 1181 C.L.V. The Role of CGMP as a Mediator of Lipolysis in Bovine Oocytes and Its Effects on
 1182 Embryo Development and Cryopreservation. *PLOS ONE* 2018, 13, e0191023,
 1183 doi:10.1371/journal.pone.0191023.
- 1184 78. Zhuan, Q.; Ma, H.; Chen, J.; Luo, Y.; Luo, Y.; Gao, L.; Hou, Y.; Zhu, S.; Fu, X. Cytoplasm Lipids
 1185 Can Be Modulated through Hormone-Sensitive Lipase and Are Related to Mitochondrial Function
 1186 in Porcine IVM Oocytes. *Reprod. Fertil. Dev.* 2020, 32, 667–675, doi:10.1071/RD19047.
- 1187 79. Zechner, R.; Zimmermann, R.; Eichmann, T.O.; Kohlwein, S.D.; Haemmerle, G.; Lass, A.; Madeo,
 1188 F. FAT SIGNALS - Lipases and Lipolysis in Lipid Metabolism and Signaling. *Cell Metab.* 2012,
 1189 15, 279–291, doi:10.1016/j.cmet.2011.12.018.
- 1190 80. Lazar, I.; Clement, E.; Attane, C.; Muller, C.; Nieto, L. A New Role for Extracellular Vesicles:
 1191 How Small Vesicles Can Feed Tumors' Big Appetite. *J. Lipid Res.* 2018, 59, 1793–1804,
 1192 doi:10.1194/jlr.R083725.
- 1193 81. Chu, B.; Zhong, L.; Dou, S.; Wang, J.; Li, J.; Wang, M.; Shi, Q.; Mei, Y.; Wu, M. MiRNA-181
 1194 Regulates Embryo Implantation in Mice through Targeting Leukemia Inhibitory Factor. *J. Mol.*
 1195 *Cell Biol.* 2015, 7, 12–22, doi:10.1093/jmcb/mjv006.
- 1196 82. Inyawilert, W.; Fu, T.-Y.; Lin, C.-T.; Tang, P.-C. Let-7-Mediated Suppression of Mucin 1
 1197 Expression in the Mouse Uterus during Embryo Implantation. *J. Reprod. Dev.* 2015, 61, 138–144,
 1198 doi:10.1262/jrd.2014-106.
- 1199 83. Burns, G.; Brooks, K.; Wildung, M.; Navakanitworakul, R.; Christenson, L.K.; Spencer, T.E.
 1200 Extracellular Vesicles in Luminal Fluid of the Ovine Uterus. *PloS One* 2014, 9, e90913,
 1201 doi:10.1371/journal.pone.0090913.
- 1202 84. Altmäe, S.; Martinez-Conejero, J.A.; Esteban, F.J.; Ruiz-Alonso, M.; Stavreus-Evers, A.;
 1203 Horcajadas, J.A.; Salumets, A. MicroRNAs MiR-30b, MiR-30d, and MiR-494 Regulate Human
 1204 Endometrial Receptivity. *Reprod. Sci.* 2013, 20, 308–317, doi:10.1177/1933719112453507.
- 1205 85. Wang, Y.; Li, J.; Kuang, D.; Wang, X.; Zhu, Y.; Xu, S.; Chen, Y.; Cheng, H.; Zhao, Q.; Duan, Y.;
 1206 et al. MiR-148b-3p Functions as a Tumor Suppressor in GISTs by Directly Targeting KIT. *Cell*
 1207 *Commun. Signal.* 2018, 16, 16, doi:10.1186/s12964-018-0228-z.
- 1208 86. Wu, H.; Jiang, K.; Guo, S.; Yang, J.; Zhao, G.; Qiu, C.; Deng, G. IFN- τ Mediated Control of
 1209 Bovine Major Histocompatibility Complex Class I Expression and Function via the Regulation of
 1210 Bta-MiR-148b/152 in Bovine Endometrial Epithelial Cells. *Front. Immunol.* 2018, 9,

- 1211 87. Malo Estepa, I.; Tinning, H.; Rosas Vasconcelos, E.J.; Fernandez-Fuertes, B.; Sánchez, J.M.;
1212 Burns, G.W.; Spencer, T.E.; Lonergan, P.; Forde, N. Protein Synthesis by Day 16 Bovine
1213 Conceptuses during the Time of Maternal Recognition of Pregnancy. *Int. J. Mol. Sci.* 2020, 21,
1214 2870, doi:10.3390/ijms21082870.
- 1215 88. Nakamura, K.; Kusama, K.; Ideta, A.; Kimura, K.; Hori, M.; Imakawa, K. Effects of MiR-98 in
1216 Intrauterine Extracellular Vesicles on Maternal Immune Regulation during the Peri-Implantation
1217 Period in Cattle. *Sci. Rep.* 2019, 9, 20330, doi:10.1038/s41598-019-56879-w.
- 1218 89. Nakamura, K.; Kusama, K.; Suda, Y.; Fujiwara, H.; Hori, M.; Imakawa, K. Emerging Role of
1219 Extracellular Vesicles in Embryo–Maternal Communication throughout Implantation Processes.
1220 *Int. J. Mol. Sci.* 2020, 21, 5523, doi:10.3390/ijms21155523.
- 1221 90. Nakamura, K.; Kusama, K.; Hori, M.; Imakawa, K. The Effect of Bta-MiR-26b in Intrauterine
1222 Extracellular Vesicles on Maternal Immune System during the Implantation Period. *Biochem.*
1223 *Biophys. Res. Commun.* 2021, 573, 100–106, doi:10.1016/j.bbrc.2021.08.019.
- 1224 91. Nakamura, K.; Kusama, K.; Ideta, A.; Imakawa, K.; Hori, M. IFNT-Independent Effects of
1225 Intrauterine Extracellular Vesicles (EVs) in Cattle. *Reproduction* 2020, 159, 503–511,
1226 doi:10.1530/REP-19-0314.
- 1227 92. Sponchiado, M.; Marei, W.F.A.; Beemster, G.T.S.; Bols, P.E.J.; Binelli, M.; Leroy, J.L.M.R.
1228 Molecular Interactions at the Bovine Embryo–Endometrial Epithelium Interface. *Reproduction*
1229 2020, 160, 887–903, doi:10.1530/REP-20-0344.
- 1230 93. Bridi, A.; Andrade, G.M.; Del Collado, M.; Sangalli, J.R.; de Ávila, A.C.F.C.M.; Motta, I.G.; da
1231 Silva, J.C.B.; Pugliesi, G.; Silva, L.A.; Meirelles, F.V.; et al. Small Extracellular Vesicles Derived
1232 from in Vivo- or in Vitro-Produced Bovine Blastocysts Have Different MiRNAs Profiles-
1233 Implications for Embryo-Maternal Recognition. *Mol. Reprod. Dev.* 2021, doi:10.1002/mrd.23527.
- 1234 94. Valadi, H.; Ekström, K.; Bossios, A.; Sjöstrand, M.; Lee, J.J.; Lötvall, J.O. Exosome-Mediated
1235 Transfer of MRNAs and MicroRNAs Is a Novel Mechanism of Genetic Exchange between Cells.
1236 *Nat. Cell Biol.* 2007, 9, 654–659, doi:10.1038/ncb1596.
- 1237 95. Skotland, T.; Sagini, K.; Sandvig, K.; Llorente, A. An Emerging Focus on Lipids in Extracellular
1238 Vesicles. *Adv. Drug Deliv. Rev.* 2020, 159, 308–321, doi:10.1016/j.addr.2020.03.002.
- 1239

1240 **Figure Legends**

1241 **Figure 1.** Experimental design.

1242 **A** EVs isolation and characterization. Oviducts (n=5) and uterine horns (n=5), ipsilateral
1243 to a Stage 1 (oviduct) or Stage 2 (uterus) corpus luteum, were flushed with PBS (1 and
1244 2 mL, respectively), and after centrifugation to remove cells and cellular debris, samples
1245 were filtered (0.22 µm) and EVs isolated by Size Exclusion Chromatography. EVs
1246 samples were concentrated by ultracentrifugation and pellets resuspended in 100 µL
1247 PBS. Thirty microliters from each of the five EVs suspensions from oviduct (150 µL)
1248 and uterus (150 µL) were pooled and from this, 5 µL were used for EVs
1249 characterization by nanoparticle tracking analysis (NTA) and 5 µL for transmission
1250 electron microscopy (TEM), and the rest was frozen at -20 °C and used in IVC. The
1251 remaining volume of the original five EVs samples (70 µL) was used for miRNA
1252 analysis. To have enough protein amount (35 µg) for EV biomarkers to be detectable by

1253 western blot, a pool of 10 oviducts (Stage 1) and uterine horns (Stage 2) flushings was
1254 obtained and prepared the same way. **B** Embryo culture in vitro. At approximately 20 h
1255 after insemination, presumptive zygotes were cultured in 4 groups: BSA: SOF with
1256 0.3% BSA (3 mg/mL w/v); dFCS: SOF with 5% dFCS; BSA-EV: SOF with 0.3% BSA
1257 supplemented with 3×10^5 EVs/mL from OF (D1 to D4) and 3×10^5 EVs/mL from UF
1258 (D4 to D9); and dFCS-EV: SOF with 5 % dFCS supplemented with 3×10^5 EVs/mL
1259 from OF (D1 to D4) and 3×10^5 EVs/mL from UF (D4 to D9). BSA and dFCS groups
1260 underwent media renewal at 96 hpi (Day 4). Blastocyst development was assessed on
1261 Days 7, 8 and 9. A representative number of Days 7–8 blastocysts from each group was
1262 assessed for quality either by vitrification/warming (survival rate at 24, 48 and 72
1263 hours) or fixed and stained for total cell number, mitochondrial activity and lipid
1264 content and analysis. In addition, Day 7–8 blastocysts were frozen in liquid nitrogen in
1265 groups of 10 and stored at -80 °C for gene expression or western blot for protein
1266 analyses. **C** miRNA contents in EVs. Total RNA in oviducts and uteri EVs samples
1267 (n=3) was extracted with a miRNeasy mini kit, reversed transcribed with the miScript
1268 PCR System and relative miRNA levels determined by qRT-PCR.

1269 **Figure 2.** OF and UF-EVs characterization.

1270 **A** Averaged finite track length adjustment Concentration/Size graphs for NTA of
1271 particles in fluid isolated from oviducts (left) and uterine horns (right). **B** Representative
1272 images from electron microscopy analyses of OF (left) and UF (right) samples. Some
1273 EVs and their sizes are indicated in the images. **C** Representative images of membranes
1274 treated for detection of EVs marker-proteins (CD9, HSP70 and ALIX) and EVs negative
1275 protein (CANX) in samples isolated from oviduct (OF-EVs) and uterus (UF-EVs). PC =
1276 positive controls (CD9 = blood, HSP70 = pancreas, ALIX = lung, CANX = urethra). MW

1277 = molecular weight marker. Numbers indicate the MW. Expected MW: CD9 = 22, 24 and
1278 35 kDa, HSP70 = ~70 kDa, ALIX = 90 kDa and CANX = 90 kDa.

1279 **Figure 3.** Representative image of embryo on Day 3 of IVC with EVs from OF and UF.
1280 **A** Representative image of embryo on Day 3 of culture in vitro with EVs from OF and **C**
1281 on Day 8 with EVs from UF. Nuclei in blue indicate cells (blastomeres) and EVs labelled
1282 with PHK67 (green). **B** Negative control for OF in D3 embryo and **D** for UF in D8
1283 embryo. 63 X.

1284 **Figure 4.** Total cell number in blastocysts IVC.
1285 Total cell number in blastocysts cultured in vitro with BSA or dFCS supplemented or not
1286 with OF-EVs (D1-4) and UF-EVs (D5-8) (BSA=57, BSA-EV=55, dFCS=58, dFCS-
1287 EV=56). Data are the means±s.e.m. Different letters differ show statistically significant
1288 differences between groups (P<0.05).

1289 **Figure 5.** Representative fluorescence images of mitochondrial activity in bovine
1290 blastocysts.

1291 **A** Representative fluorescence images of mitochondrial activity in bovine blastocysts
1292 cultured in vitro in medium with BSA, BSA-EV, dFCS and dFCS-EV . Images captured
1293 on 63X objective. **B** Quantification of mitochondria fluorescence intensity in arbitrary
1294 unites (au) in blastocysts cultured in vitro with BSA or dFCS supplemented or not with
1295 OF-EVs (D1-4) and UF-EVs (D5-8). (BSA=29, BSA-EV =29, dFCS=33, dFCS-EV =27).
1296 Data are the means±s.e.m. * Indicates the group differs significantly from the others
1297 (P<0.05).

1298 **Figure 6.** Representative fluorescence images of lipid droplets in bovine blastocysts.
1299 **A** Representative fluorescence images of lipid droplets in bovine blastocysts cultured in
1300 vitro in medium with BSA, BSA-EV, dFCS and dFCS-EV. Images captured on 63X
1301 objective. **B** Quantification of total area of lipids in D7-8 blastocysts cultured in vitro with

1302 BSA or dFCS supplemented or not with OF-EVs (D1-4) and UF-EVs (D5-8) (BSA=28,
1303 BSA-EV =26, dFCS=25, dFCS-EV =29). Data are the means±s.e.m. Different letters
1304 differ show statistically significant differences between groups (P<0.05).

1305 **Figure 7.** Relative mRNA abundance of lipid metabolism-related genes in blastocysts.

1306 Relative mRNA abundance of lipid metabolism-related genes in blastocysts cultured in
1307 vitro with BSA or dFCS only or supplemented with OF-s (D1-4) and UF-EVs (D5-8)
1308 (BSA, BSA-EV, dFCS and dFCS-EV). Bars represent the relative abundance of the
1309 transcripts analysed and normalized to *H2AFZ* and *ACTB* as housekeeping genes. The
1310 experimental groups are represented by columns. Data are the means±s.e.m. Different
1311 letters differ show statistically significant differences between groups (P<0.05).

1312 **Figure 8.** pHSL phosphorylation levels in bovine blastocysts.

1313 Effect of in vitro culture medium with BSA or dFCS supplemented or not with OF-EVs
1314 (D1-4) followed by UF-EVs (D5-8) on pHSL phosphorylation levels in bovine
1315 blastocysts. **A** pHSL phosphorylation level. Expression levels were normalized to the
1316 abundance of endogenous control actin. Phosphorylation level was expressed as
1317 pHSL/HSL. Data are expressed as means±s.e.m. *Indicates the group differs significantly
1318 from the others (P<0.05). **B** Representative images of membranes treated for detection of
1319 lipolysis protein, total HSL and phosphorylated p-HSL, and ACTB.

1320 **Figure 9.** Relative abundance of miRNAs in EVs from OF and UF in bovine embryos.

1321 Relative abundance of miRNAs in EVs from OF and UF used in the in vitro culture of
1322 bovine embryos. From 20 differentially expressed miRNAs, 19 were upregulated in UF-
1323 EVs and one* in OF-EVs (P<0.05).

Figures

Figure 1

Experimental design. A EVs isolation and characterization. Oviducts (n=5) and uterine horns (n=5), ipsilateral to a Stage 1 (oviduct) or Stage 2 (uterus) corpus luteum, were flushed with PBS (1 and 2 mL, respectively), and after centrifugation to remove cells and cellular debris, samples were filtered (0.22 µm) and EVs isolated by Size Exclusion Chromatography. EVs samples were concentrated by ultracentrifugation and pellets resuspended in 100 µL PBS. Thirty microliters from each of the five EVs suspensions from oviduct (150 µL) and uterus (150 µL) were pooled and from this, 5 µL were used for EVs characterization by nanoparticle tracking analysis (NTA) and 5 µL for transmission electron microscopy (TEM), and the rest was frozen at -20 °C and used in IVC. The remaining volume of the original five EVs samples (70 µL) was used for miRNA analysis. To have enough protein amount (35 µg) for EV biomarkers to be detectable by western blot, a pool of 10 oviducts (Stage 1) and uterine horns (Stage 2) flushings was obtained and prepared the same way. B Embryo culture in vitro. At approximately 20 h after insemination, presumptive zygotes were cultured in 4 groups: BSA: SOF with 0.3% BSA (3 mg/mL w/v); dFCS: SOF with 5% dFCS; BSA-EV: SOF with 0.3% BSA supplemented with 3×10⁵ EVs/mL from OF (D1 to D4) and 3×10⁵ EVs/mL from UF (D4 to D9); and dFCS-EV: SOF with 5 % dFCS supplemented with 3×10⁵ EVs/mL from OF (D1 to D4) and 3×10⁵ EVs/mL from UF (D4 to D9). BSA and dFCS groups underwent media renewal at 96 hpi (Day 4). Blastocyst development was assessed on Days 7, 8 and 9. A representative number of Days 7–8 blastocysts from each group was assessed for quality either by vitrification/warming (survival rate at 24, 48 and 72 hours) or fixed and stained for total cell number, mitochondrial activity and lipid content and analysis. In addition, Day 7–8 blastocysts were frozen in liquid nitrogen in groups of 10 and stored at -80 °C for gene expression or western blot for protein analyses. C miRNA contents in EVs. Total RNA in oviducts and uteri EVs samples (n=3) was extracted with a miRNeasy mini kit, reversed transcribed with the miScript PCR System and relative miRNA levels determined by qRT-PCR.

Figure 2

OF and UF-EVs characterization.

A Averaged finite track length adjustment Concentration/Size graphs for NTA of particles in fluid isolated from oviducts (left) and uterine horns (right). B Representative images from electron microscopy analyses of OF (left) and UF (right) samples. Some EVs and their sizes are indicated in the images. C Representative images of membranes treated for detection of EVs marker-proteins (CD9, HSP70 and ALIX) and EVs negative protein (CANX) in samples isolated from oviduct (OF-EVs) and uterus (UF-EVs).

PC = positive controls (CD9 = blood, HSP70 = pancreas, ALIX = lung, CANX = urethra). MW = molecular weight marker. Numbers indicate the MW. Expected MW: CD9 = 22, 24 and 35 kDa, HSP70 = ~70 kDa, ALIX = 90 kDa and CANX = 90 kDa.

Figure 3

Representative image of embryo on Day 3 of IVC with EVs from OF and UF.

A Representative image of embryo on Day 3 of culture in vitro with EVs from OF and C on Day 8 with EVs from UF. Nuclei in blue indicate cells (blastomeres) and EVs labelled with PHK67 (green). B Negative control for OF in D3 embryo and D for UF in D8 embryo. 63 X.




Figure 4

Total cell number in blastocysts IVC.

Total cell number in blastocysts cultured in vitro with BSA or dFCS supplemented or not with OF-EVs (D1-4) and UF-EVs (D5-8) (BSA=57, BSA-EV=55, dFCS=58, dFCS- EV=56). Data are the means±s.e.m. Different letters differ show statistically significant differences between groups (P<0.05).

Figure 5

Representative fluorescence images of mitochondrial activity in bovine blastocysts.

A Representative fluorescence images of mitochondrial activity in bovine blastocysts cultured in vitro in medium with BSA, BSA-EV, dFCS and dFCS-EV. Images captured on 63X objective. B Quantification of mitochondria fluorescence intensity in arbitrary unites (au) in blastocysts cultured in vitro with BSA or dFCS supplemented or not with OF-EVs (D1-4) and UF-EVs (D5-8). (BSA=29, BSA-EV =29, dFCS=33, dFCS-EV =27). Data are the means \pm s.e.m. * Indicates the group differs significantly from the others (P<0.05).

Figure 6

Representative fluorescence images of lipid droplets in bovine blastocysts.

A Representative fluorescence images of lipid droplets in bovine blastocysts cultured in vitro in medium with BSA, BSA-EV, dFCS and dFCS-EV. Images captured on 63X objective. B Quantification of total area of lipids in D7-8 blastocysts cultured in vitro with BSA or dFCS supplemented or not with OF-EVs (D1-4) and UF-EVs (D5-8) (BSA=28, BSA-EV =26, dFCS=25, dFCS-EV =29). Data are the means \pm s.e.m. Different letters differ show statistically significant differences between groups (P<0.05).




Figure 7

Relative mRNA abundance of lipid metabolism-related genes in blastocysts.

Relative mRNA abundance of lipid metabolism-related genes in blastocysts cultured in vitro with BSA or dFCS only or supplemented with OF-s (D1-4) and UF-EVs (D5-8) (BSA, BSA-EV, dFCS and dFCS-EV). Bars represent the relative abundance of the transcripts analysed and normalized to H2AFZ and ACTB as housekeeping genes. The experimental groups are represented by columns. Data are the means \pm s.e.m. Different letters differ show statistically significant differences between groups (P<0.05).




Figure 8

pHSL phosphorylation levels in bovine blastocysts.

Effect of in vitro culture medium with BSA or dFCS supplemented or not with OF-EVs (D1-4) followed by UF-EVs (D5-8) on pHSL phosphorylation levels in bovine blastocysts. A pHSL phosphorylation level. Expression levels were normalized to the abundance of endogenous control actin. Phosphorylation level was expressed as pHSL/HSL. Data are expressed as means \pm s.e.m. *Indicates the group differs significantly from the others ($P < 0.05$). B Representative images of membranes treated for detection of lipolysis protein, total HSL and phosphorylated p-HSL, and ACTB.

Figure 9

Relative abundance of miRNAs in EVs from OF and UF in bovine embryos.

Relative abundance of miRNAs in EVs from OF and UF used in the in vitro culture of bovine embryos. From 20 differentially expressed miRNAs, 19 were upregulated in UF-EVs and one* in OF-EVs ($P < 0.05$).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplementarytable1.docx](#)
- [Supplementarytable2.docx](#)